OA16801A - Compounds for the treatment of addiction. - Google Patents
Compounds for the treatment of addiction. Download PDFInfo
- Publication number
- OA16801A OA16801A OA1201300542 OA16801A OA 16801 A OA16801 A OA 16801A OA 1201300542 OA1201300542 OA 1201300542 OA 16801 A OA16801 A OA 16801A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- hydrogen
- optionally substituted
- compound
- benzyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 250
- 206010012335 Dependence Diseases 0.000 title claims abstract description 22
- -1 amphetamines Chemical compound 0.000 claims abstract description 85
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 60
- SNICXCGAKADSCV-JTQLQIEISA-N Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims abstract description 41
- 229960002715 Nicotine Drugs 0.000 claims abstract description 41
- 229930015196 nicotine Natural products 0.000 claims abstract description 41
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229960003638 dopamine Drugs 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 241000124008 Mammalia Species 0.000 claims abstract description 10
- 239000000126 substance Substances 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 108
- 239000001257 hydrogen Substances 0.000 claims description 108
- 125000000217 alkyl group Chemical group 0.000 claims description 95
- 239000000203 mixture Substances 0.000 claims description 75
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 73
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims description 62
- 125000001072 heteroaryl group Chemical group 0.000 claims description 61
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 49
- 150000002148 esters Chemical class 0.000 claims description 43
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
- 125000000623 heterocyclic group Chemical group 0.000 claims description 39
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 36
- 125000005843 halogen group Chemical group 0.000 claims description 31
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 28
- 125000001153 fluoro group Chemical group F* 0.000 claims description 24
- 125000003107 substituted aryl group Chemical group 0.000 claims description 22
- 125000002947 alkylene group Chemical group 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 20
- 125000002252 acyl group Chemical group 0.000 claims description 19
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- 125000004442 acylamino group Chemical group 0.000 claims description 17
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 13
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 239000000651 prodrug Substances 0.000 claims description 9
- 229940002612 prodrugs Drugs 0.000 claims description 9
- SPADNYVJQZNTKZ-UHFFFAOYSA-N [4-[4-[[(2,6-dichlorobenzoyl)amino]methyl]phenyl]-2-oxopyridin-1-yl]methyl dihydrogen phosphate Chemical compound O=C1N(COP(O)(=O)O)C=CC(C=2C=CC(CNC(=O)C=3C(=CC=CC=3Cl)Cl)=CC=2)=C1 SPADNYVJQZNTKZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 8
- 230000003247 decreasing Effects 0.000 claims description 7
- 125000004475 heteroaralkyl group Chemical group 0.000 claims description 7
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims 19
- 238000004519 manufacturing process Methods 0.000 claims 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N Morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract description 2
- 229960005181 morphine Drugs 0.000 abstract description 2
- 229930014694 morphine Natural products 0.000 abstract description 2
- 229960003920 ***e Drugs 0.000 abstract 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 1
- ZPUCINDJVBIVPJ-BARDWOONSA-N ***e Natural products O([C@@H]1C[C@H]2CC[C@H](N2C)[C@@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-BARDWOONSA-N 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 70
- 125000001424 substituent group Chemical group 0.000 description 66
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 238000006243 chemical reaction Methods 0.000 description 44
- 230000035492 administration Effects 0.000 description 39
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 36
- 125000003118 aryl group Chemical group 0.000 description 34
- 125000003545 alkoxy group Chemical group 0.000 description 31
- 239000003981 vehicle Substances 0.000 description 31
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 29
- 150000001412 amines Chemical class 0.000 description 27
- 239000003814 drug Substances 0.000 description 27
- 229910052736 halogen Inorganic materials 0.000 description 26
- 150000002367 halogens Chemical class 0.000 description 26
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 229940079593 drugs Drugs 0.000 description 25
- 239000002253 acid Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 23
- 230000002401 inhibitory effect Effects 0.000 description 23
- 125000003342 alkenyl group Chemical group 0.000 description 22
- 125000004181 carboxyalkyl group Chemical group 0.000 description 22
- 125000000392 cycloalkenyl group Chemical group 0.000 description 22
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 22
- 125000004432 carbon atoms Chemical group C* 0.000 description 21
- 235000013305 food Nutrition 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 20
- 235000019439 ethyl acetate Nutrition 0.000 description 20
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 20
- 239000003826 tablet Substances 0.000 description 20
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- 125000000304 alkynyl group Chemical group 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 102000010909 EC 1.4.3.4 Human genes 0.000 description 17
- 108010062431 EC 1.4.3.4 Proteins 0.000 description 17
- 125000005418 aryl aryl group Chemical group 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- SJRJJKPEHAURKC-UHFFFAOYSA-N n-methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 16
- 239000000376 reactant Substances 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- 125000004429 atoms Chemical group 0.000 description 15
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 14
- 125000002877 alkyl aryl group Chemical group 0.000 description 13
- 125000004414 alkyl thio group Chemical group 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 230000002354 daily Effects 0.000 description 12
- 239000012074 organic phase Substances 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 239000007858 starting material Substances 0.000 description 12
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 11
- 125000004423 acyloxy group Chemical group 0.000 description 11
- 125000000033 alkoxyamino group Chemical group 0.000 description 11
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 11
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 11
- 125000005110 aryl thio group Chemical group 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 11
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 11
- 125000004468 heterocyclylthio group Chemical group 0.000 description 11
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 11
- 125000000468 ketone group Chemical group 0.000 description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 11
- 230000002829 reduced Effects 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 11
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 11
- 150000003573 thiols Chemical class 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- 239000003054 catalyst Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 125000005553 heteroaryloxy group Chemical group 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 229910052763 palladium Inorganic materials 0.000 description 10
- 239000001184 potassium carbonate Substances 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- KQROHCSYOGBQGJ-UHFFFAOYSA-N 5-Hydroxytryptophol Chemical compound C1=C(O)C=C2C(CCO)=CNC2=C1 KQROHCSYOGBQGJ-UHFFFAOYSA-N 0.000 description 9
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 125000005368 heteroarylthio group Chemical group 0.000 description 9
- 230000001965 increased Effects 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 9
- 238000006069 Suzuki reaction reaction Methods 0.000 description 8
- 230000006399 behavior Effects 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 8
- 230000001684 chronic Effects 0.000 description 8
- 229910052805 deuterium Inorganic materials 0.000 description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 238000001802 infusion Methods 0.000 description 8
- 150000007529 inorganic bases Chemical class 0.000 description 8
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 8
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 230000002787 reinforcement Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- KHQRDAXRUBHKHN-UHFFFAOYSA-N tert-butyl N-[[4-[2-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]phenyl]methyl]carbamate Chemical compound C1=CC(CNC(=O)OC(C)(C)C)=CC=C1C1=CC=NC(OC(C)(C)C)=C1 KHQRDAXRUBHKHN-UHFFFAOYSA-N 0.000 description 8
- 230000001225 therapeutic Effects 0.000 description 8
- YUESGEMMPRTPEM-UHFFFAOYSA-N 4-[4-(aminomethyl)phenyl]-1H-pyridin-2-one Chemical compound C1=CC(CN)=CC=C1C1=CC(=O)NC=C1 YUESGEMMPRTPEM-UHFFFAOYSA-N 0.000 description 7
- AUZONCFQVSMFAP-UHFFFAOYSA-N Disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 7
- 229960002563 Disulfiram Drugs 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004316 Oxidoreductases Human genes 0.000 description 7
- 108090000854 Oxidoreductases Proteins 0.000 description 7
- 150000001408 amides Chemical class 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 125000002346 iodo group Chemical group I* 0.000 description 7
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229940086542 triethylamine Drugs 0.000 description 7
- 206010001584 Alcohol abuse Diseases 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Carbodicyclohexylimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 201000003082 alcohol use disease Diseases 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 235000007240 daidzein Nutrition 0.000 description 6
- 238000010511 deprotection reaction Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 125000005844 heterocyclyloxy group Chemical group 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000012026 peptide coupling reagents Substances 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 238000003825 pressing Methods 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- OBFAPCIUSYHFIE-UHFFFAOYSA-N (5-hydroxyindol-3-yl)acetaldehyde Chemical compound OC1=CC=C2NC=C(CC=O)C2=C1 OBFAPCIUSYHFIE-UHFFFAOYSA-N 0.000 description 5
- 102100006683 ALDH2 Human genes 0.000 description 5
- 208000007848 Alcoholism Diseases 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 108010009513 Mitochondrial Aldehyde Dehydrogenase Proteins 0.000 description 5
- 240000008962 Nicotiana tabacum Species 0.000 description 5
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000004470 heterocyclooxy group Chemical group 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 230000000051 modifying Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 5
- 239000000546 pharmaceutic aid Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 150000003222 pyridines Chemical class 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 125000005017 substituted alkenyl group Chemical group 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- 229940043253 Butylated Hydroxyanisole Drugs 0.000 description 4
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 4
- CZBZUDVBLSSABA-UHFFFAOYSA-N Butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- YCIMNLLNPGFGHC-UHFFFAOYSA-N Catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 4
- 102100001422 MAOA Human genes 0.000 description 4
- 101710004794 MAOA Proteins 0.000 description 4
- 102100001420 MAOB Human genes 0.000 description 4
- 101710040126 MAOB Proteins 0.000 description 4
- BDNKZNFMNDZQMI-UHFFFAOYSA-N N,N'-Diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
- VIAFLMPQBHAMLI-UHFFFAOYSA-N PyBOP Chemical compound F[P-](F)(F)(F)(F)F.C1CCCN1[P+](N1CCCC1)(N1CCCC1)ON1C2=CC=CC=C2N=N1 VIAFLMPQBHAMLI-UHFFFAOYSA-N 0.000 description 4
- 210000002700 Urine Anatomy 0.000 description 4
- 230000001154 acute Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 201000007930 alcohol dependence Diseases 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000002438 mitochondrial Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 201000008430 obsessive-compulsive disease Diseases 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical group CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 description 4
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WSNUORLCXYILLL-UHFFFAOYSA-N 2,6-dichloro-4-(2-methoxyethoxy)benzoic acid Chemical compound COCCOC1=CC(Cl)=C(C(O)=O)C(Cl)=C1 WSNUORLCXYILLL-UHFFFAOYSA-N 0.000 description 3
- IADQVXRMSNIUEL-UHFFFAOYSA-N 3,4-Dihydroxyphenylacetaldehyde Chemical compound OC1=CC=C(CC=O)C=C1O IADQVXRMSNIUEL-UHFFFAOYSA-N 0.000 description 3
- NCDASAXVWHEWJS-UHFFFAOYSA-N 4-bromo-2-[(2-methylpropan-2-yl)oxy]pyridine Chemical compound CC(C)(C)OC1=CC(Br)=CC=N1 NCDASAXVWHEWJS-UHFFFAOYSA-N 0.000 description 3
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 3
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 3
- 229940120060 Heroin Drugs 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 210000004731 Jugular Veins Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 3
- IMYZQPCYWPFTAG-IQJOONFLSA-N Mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N Naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 3
- 229960003086 Naltrexone Drugs 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N Nicotinamide adenine dinucleotide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 229940076279 Serotonin Drugs 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M Sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 description 3
- 229960004047 acamprosate Drugs 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 150000001543 aryl boronic acids Chemical class 0.000 description 3
- 230000003542 behavioural Effects 0.000 description 3
- 239000004305 biphenyl Substances 0.000 description 3
- 235000010290 biphenyl Nutrition 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 230000005587 bubbling Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000035569 catabolism Effects 0.000 description 3
- 210000004027 cells Anatomy 0.000 description 3
- 235000019504 cigarettes Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 239000002285 corn oil Substances 0.000 description 3
- 235000019788 craving Nutrition 0.000 description 3
- 125000006165 cyclic alkyl group Chemical group 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229960002069 diamorphine Drugs 0.000 description 3
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 125000005842 heteroatoms Chemical group 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 3
- 229930012948 isoflavones Natural products 0.000 description 3
- 235000008696 isoflavones Nutrition 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960002525 mecamylamine Drugs 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 238000005897 peptide coupling reaction Methods 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 150000003141 primary amines Chemical class 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 230000000391 smoking Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 230000002459 sustained Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- XWMVMWTVLSLJGY-IUXQBBRLSA-N (2S,5R,6R)-6-[(2-carboxy-2-thiophen-3-ylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C=1C=CSC=1 XWMVMWTVLSLJGY-IUXQBBRLSA-N 0.000 description 2
- BVYUYDBWQMSOKM-UHFFFAOYSA-N (4-bromophenyl)methanamine;hydron;chloride Chemical compound Cl.NCC1=CC=C(Br)C=C1 BVYUYDBWQMSOKM-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N (E)-but-2-enedioate;hydron Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- BPYMXAABTHYLOT-UHFFFAOYSA-N 2,6-dichloro-4-(2-methoxyethoxy)benzaldehyde Chemical compound COCCOC1=CC(Cl)=C(C=O)C(Cl)=C1 BPYMXAABTHYLOT-UHFFFAOYSA-N 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 2
- 229940005513 ANTIDEPRESSANTS Drugs 0.000 description 2
- 206010002855 Anxiety Diseases 0.000 description 2
- 206010057666 Anxiety disease Diseases 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 210000004556 Brain Anatomy 0.000 description 2
- 229940028978 Brevital Drugs 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N Carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 206010010144 Completed suicide Diseases 0.000 description 2
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 230000036499 Half live Effects 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 230000036650 Metabolic stability Effects 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 2
- 208000010125 Myocardial Infarction Diseases 0.000 description 2
- 235000009421 Myristica fragrans Nutrition 0.000 description 2
- MPVWFNJPFIILMB-UHFFFAOYSA-N N-[(4-bromo-3-methylphenyl)methyl]-2,6-dichlorobenzamide Chemical compound C1=C(Br)C(C)=CC(CNC(=O)C=2C(=CC=CC=2Cl)Cl)=C1 MPVWFNJPFIILMB-UHFFFAOYSA-N 0.000 description 2
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N P-Toluenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M Potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N Pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M Sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N Theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 229940027257 Timentin Drugs 0.000 description 2
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Trimethylglycine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- WMXZOWNNBROPGP-UHFFFAOYSA-N [4-[[(2,6-dichlorobenzoyl)amino]methyl]phenyl]boronic acid Chemical compound C1=CC(B(O)O)=CC=C1CNC(=O)C1=C(Cl)C=CC=C1Cl WMXZOWNNBROPGP-UHFFFAOYSA-N 0.000 description 2
- IVPKEUMTZCSLMM-UHFFFAOYSA-O [methoxy(methylamino)methylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CNC(OC)=[N+](C)C IVPKEUMTZCSLMM-UHFFFAOYSA-O 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000240 adjuvant Effects 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001430 anti-depressive Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 2
- 230000002238 attenuated Effects 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N carbodiimide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 2
- 230000024881 catalytic activity Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000007822 coupling agent Substances 0.000 description 2
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 description 2
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 2
- 150000001950 daidzein derivatives Chemical class 0.000 description 2
- 230000003111 delayed Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 125000005265 dialkylamine group Chemical group 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 239000002612 dispersion media Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing Effects 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 230000000155 isotopic Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000001115 mace Substances 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000002503 metabolic Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDXZREBVGAGZHS-UHFFFAOYSA-M methohexital sodium Chemical compound [Na+].CCC#CC(C)C1(CC=C)C(=O)N=C([O-])N(C)C1=O KDXZREBVGAGZHS-UHFFFAOYSA-M 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 229950006238 nadide Drugs 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000000926 neurological Effects 0.000 description 2
- 238000002670 nicotine replacement therapy Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- KEDPUQKUZHYBGW-UHFFFAOYSA-O phosphanium;hexafluorophosphate Chemical compound [PH4+].F[P-](F)(F)(F)(F)F KEDPUQKUZHYBGW-UHFFFAOYSA-O 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000002142 suicide Effects 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003491 tear gas Substances 0.000 description 2
- 125000005270 trialkylamine group Chemical group 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- DYTUAOUIQFNOIH-HTQZYQBOSA-L (2S,3S)-2,3-diethyl-2,3-dihydroxybutanedioate Chemical compound CC[C@@](O)(C([O-])=O)[C@@](O)(CC)C([O-])=O DYTUAOUIQFNOIH-HTQZYQBOSA-L 0.000 description 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBONBWJSFMTXLE-UHFFFAOYSA-N 2,3-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1Cl YBONBWJSFMTXLE-UHFFFAOYSA-N 0.000 description 1
- KORCHKZQENWWFC-UHFFFAOYSA-N 2,6-dichloro-4-(2-methoxyethoxy)-N-[[4-[2-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]phenyl]methyl]benzamide Chemical compound ClC1=CC(OCCOC)=CC(Cl)=C1C(=O)NCC1=CC=C(C=2C=C(OC(C)(C)C)N=CC=2)C=C1 KORCHKZQENWWFC-UHFFFAOYSA-N 0.000 description 1
- WWFRBIPLCLSKNH-UHFFFAOYSA-N 2,6-dichloro-4-hydroxybenzaldehyde Chemical compound OC1=CC(Cl)=C(C=O)C(Cl)=C1 WWFRBIPLCLSKNH-UHFFFAOYSA-N 0.000 description 1
- AHIMTVMUXNVJKV-UHFFFAOYSA-N 2,6-dichloro-N-[[4-[2-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]phenyl]methyl]benzamide Chemical compound C1=NC(OC(C)(C)C)=CC(C=2C=CC(CNC(=O)C=3C(=CC=CC=3Cl)Cl)=CC=2)=C1 AHIMTVMUXNVJKV-UHFFFAOYSA-N 0.000 description 1
- MRUDNSFOFOQZDA-UHFFFAOYSA-N 2,6-dichlorobenzoic acid Chemical compound OC(=O)C1=C(Cl)C=CC=C1Cl MRUDNSFOFOQZDA-UHFFFAOYSA-N 0.000 description 1
- ARCMHOCAICWNFM-UHFFFAOYSA-N 2,6-dimethyl-N-[[4-(2-oxopiperidin-4-yl)phenyl]methyl]benzamide Chemical compound CC1=CC=CC(C)=C1C(=O)NCC1=CC=C(C2CC(=O)NCC2)C=C1 ARCMHOCAICWNFM-UHFFFAOYSA-N 0.000 description 1
- YRULUXDRMGWMDA-UHFFFAOYSA-K 2-(2-ethylhexanoyloxy)ethanethiolate;methyltin(3+) Chemical compound CCCCC(CC)C(=O)OCCS[Sn](C)(SCCOC(=O)C(CC)CCCC)SCCOC(=O)C(CC)CCCC YRULUXDRMGWMDA-UHFFFAOYSA-K 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical class CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- VUKAUDKDFVSVFT-UHFFFAOYSA-N 2-[6-[4,5-bis(2-hydroxypropoxy)-2-(2-hydroxypropoxymethyl)-6-methoxyoxan-3-yl]oxy-4,5-dimethoxy-2-(methoxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)-5-methoxyoxane-3,4-diol Chemical compound COC1C(OC)C(OC2C(C(O)C(OC)C(CO)O2)O)C(COC)OC1OC1C(COCC(C)O)OC(OC)C(OCC(C)O)C1OCC(C)O VUKAUDKDFVSVFT-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-M 2-carboxy-6-propylphenolate Chemical class CCCC1=CC=CC(C([O-])=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-M 0.000 description 1
- LREJWAPLNAZPIV-UHFFFAOYSA-N 2-chloro-3,6-difluoro-N-[[4-[2-[(2-methylpropan-2-yl)oxy]pyridin-4-yl]phenyl]methyl]benzamide Chemical compound C1=NC(OC(C)(C)C)=CC(C=2C=CC(CNC(=O)C=3C(=C(F)C=CC=3F)Cl)=CC=2)=C1 LREJWAPLNAZPIV-UHFFFAOYSA-N 0.000 description 1
- COWJYTLVSFKOPM-UHFFFAOYSA-N 2-chloro-3,6-difluorobenzoic acid Chemical compound OC(=O)C1=C(F)C=CC(F)=C1Cl COWJYTLVSFKOPM-UHFFFAOYSA-N 0.000 description 1
- WJYAYXKXZNITAZ-UHFFFAOYSA-N 2-chloro-3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1Cl WJYAYXKXZNITAZ-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- MWOOKDULMBMMPN-UHFFFAOYSA-N 3-(2-ethyl-1,2-oxazol-2-ium-5-yl)benzenesulfonate Chemical compound O1[N+](CC)=CC=C1C1=CC=CC(S([O-])(=O)=O)=C1 MWOOKDULMBMMPN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- PFBZWBJAFXWUSF-UHFFFAOYSA-N 5-HT 5-hydroxytryptamine Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1.C1=C(O)C=C2C(CCN)=CNC2=C1 PFBZWBJAFXWUSF-UHFFFAOYSA-N 0.000 description 1
- ZZOKVYOCRSMTSS-UHFFFAOYSA-N 9H-fluoren-9-ylmethyl carbamate Chemical compound C1=CC=C2C(COC(=O)N)C3=CC=CC=C3C2=C1 ZZOKVYOCRSMTSS-UHFFFAOYSA-N 0.000 description 1
- 230000035502 ADME Effects 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N Acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N Benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- JHLNERQLKQQLRZ-UHFFFAOYSA-N Calcium silicate Chemical compound [Ca+2].[Ca+2].[O-][Si]([O-])([O-])[O-] JHLNERQLKQQLRZ-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Calypsol Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 240000000218 Cannabis sativa Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000008787 Cardiovascular Disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N Cetyl alcohol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- OSASVXMJTNOKOY-UHFFFAOYSA-N Chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
- 229960004926 Chlorobutanol Drugs 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N Chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- VZWXIQHBIQLMPN-UHFFFAOYSA-N Chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000008208 Craniocerebral Trauma Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000699662 Cricetomys gambianus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N DMSO dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N Dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- RRQYJINTUHWNHW-UHFFFAOYSA-N Diethylene glycol diethyl ether Chemical compound CCOCCOCCOCC RRQYJINTUHWNHW-UHFFFAOYSA-N 0.000 description 1
- 206010013663 Drug dependence Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 229940112141 Dry Powder Inhaler Drugs 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- HEZNVIYQEUHLNI-UHFFFAOYSA-N Ethiofencarb Chemical compound CCSCC1=CC=CC=C1OC(=O)NC HEZNVIYQEUHLNI-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229940012017 Ethylenediamine Drugs 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- IRXSLJNXXZKURP-UHFFFAOYSA-N Fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 229960002442 Glucosamine Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 206010019070 Hallucination, auditory Diseases 0.000 description 1
- 206010019233 Headache Diseases 0.000 description 1
- 208000003698 Heroin Dependence Diseases 0.000 description 1
- LJQLCJWAZJINEB-UHFFFAOYSA-N Hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F LJQLCJWAZJINEB-UHFFFAOYSA-N 0.000 description 1
- 229960002885 Histidine Drugs 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N Indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 206010022437 Insomnia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N Isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 206010024324 Leukaemias Diseases 0.000 description 1
- 208000009856 Lung Disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N Malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 230000035633 Metabolized Effects 0.000 description 1
- 229940117841 Methacrylic Acid Copolymer Drugs 0.000 description 1
- 210000001589 Microsomes Anatomy 0.000 description 1
- 210000003470 Mitochondria Anatomy 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- UBRJKNBHOXDPEU-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-2,6-dichloro-4-(2-methoxyethoxy)benzamide Chemical compound ClC1=CC(OCCOC)=CC(Cl)=C1C(=O)NCC1=CC=C(Br)C=C1 UBRJKNBHOXDPEU-UHFFFAOYSA-N 0.000 description 1
- YLYCIYMRALNJIK-UHFFFAOYSA-N N-[(4-bromophenyl)methyl]-2-chloro-3,6-difluorobenzamide Chemical compound FC1=CC=C(F)C(C(=O)NCC=2C=CC(Br)=CC=2)=C1Cl YLYCIYMRALNJIK-UHFFFAOYSA-N 0.000 description 1
- WXJKGOQQYUVNQW-YDXJMRNDSA-N N-[1-[(2R,3R,4R,5R)-5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxy-3-methoxyoxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide Chemical compound C([C@@H]1[C@@H](O)[C@H]([C@@H](O1)N1C(N=C(NC(=O)C=2C=CC=CC=2)C=C1)=O)OC)OC(C=1C=CC(OC)=CC=1)(C=1C=CC(OC)=CC=1)C1=CC=CC=C1 WXJKGOQQYUVNQW-YDXJMRNDSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HGUZQMQXAHVIQC-UHFFFAOYSA-N N-methylethenamine Chemical group CNC=C HGUZQMQXAHVIQC-UHFFFAOYSA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M N-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 229940052665 NADH Drugs 0.000 description 1
- 229910003813 NRa Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010057852 Nicotine dependence Diseases 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N OBO Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 206010033616 Pancreatic disease Diseases 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- RDOWQLZANAYVLL-UHFFFAOYSA-N Phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Chemical compound C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N Phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- 229950000688 Phenothiazine Drugs 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N Phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 229940023488 Pill Drugs 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 208000004358 Polyneuropathy Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- 206010061920 Psychotic disease Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 229940107700 Pyruvic Acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 206010039911 Seizure Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229940083599 Sodium Iodide Drugs 0.000 description 1
- 229940075582 Sorbic Acid Drugs 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N TFA trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J Tetrasodium pyrophosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229960004559 Theobromine Drugs 0.000 description 1
- 229940033663 Thimerosal Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L Thiomersal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 230000036335 Tissue distribution Effects 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N Trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N Xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 Xylazine Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- HUZNRXFJHYNUMV-UHFFFAOYSA-N [4-(aminomethyl)phenyl]boronic acid;hydron;chloride Chemical compound Cl.NCC1=CC=C(B(O)O)C=C1 HUZNRXFJHYNUMV-UHFFFAOYSA-N 0.000 description 1
- MUBGEKQUCSEECZ-UHFFFAOYSA-N [4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]phenyl]boronic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(B(O)O)C=C1 MUBGEKQUCSEECZ-UHFFFAOYSA-N 0.000 description 1
- AQPNIQKQZUWFGB-UHFFFAOYSA-O [NH3+]C.F[P-](F)(F)(F)(F)F Chemical compound [NH3+]C.F[P-](F)(F)(F)(F)F AQPNIQKQZUWFGB-UHFFFAOYSA-O 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical compound N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- UNXISIRQWPTTSN-UHFFFAOYSA-N boron;2,3-dimethylbutane-2,3-diol Chemical compound [B].[B].CC(C)(O)C(C)(C)O UNXISIRQWPTTSN-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical group 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001722 carbon compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 231100000060 cardiovascular toxicity Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 230000001055 chewing Effects 0.000 description 1
- 238000010568 chiral column chromatography Methods 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 235000019571 color Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 231100000867 compulsive behavior Toxicity 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001143 conditioned Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005824 corn Nutrition 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000001419 dependent Effects 0.000 description 1
- 201000008286 diarrhea Diseases 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- LCSNDSFWVKMJCT-UHFFFAOYSA-N dicyclohexyl-(2-phenylphenyl)phosphane Chemical group C1CCCCC1P(C=1C(=CC=CC=1)C=1C=CC=CC=1)C1CCCCC1 LCSNDSFWVKMJCT-UHFFFAOYSA-N 0.000 description 1
- YSAVZVORKRDODB-PHDIDXHHSA-N diethyl (2R,3R)-2,3-dihydroxybutanedioate Chemical compound CCOC(=O)[C@H](O)[C@@H](O)C(=O)OCC YSAVZVORKRDODB-PHDIDXHHSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 201000010046 dilated cardiomyopathy Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide DMF Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- XEBCWEDRGPSHQH-YUMQZZPRSA-N dipropan-2-yl (2S,3S)-2,3-dihydroxybutanedioate Chemical compound CC(C)OC(=O)[C@@H](O)[C@H](O)C(=O)OC(C)C XEBCWEDRGPSHQH-YUMQZZPRSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- PFKZNROEIPPDRE-UHFFFAOYSA-N ditert-butyl [4-[4-[[(2,6-dichlorobenzoyl)amino]methyl]phenyl]-2-oxopyridin-1-yl]methyl phosphate Chemical compound O=C1N(COP(=O)(OC(C)(C)C)OC(C)(C)C)C=CC(C=2C=CC(CNC(=O)C=3C(=CC=CC=3Cl)Cl)=CC=2)=C1 PFKZNROEIPPDRE-UHFFFAOYSA-N 0.000 description 1
- YEWZQCDRZRYAEB-UHFFFAOYSA-N ditert-butyl hydrogen phosphate Chemical compound CC(C)(C)OP(O)(=O)OC(C)(C)C YEWZQCDRZRYAEB-UHFFFAOYSA-N 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006180 eating disease Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N ethanolamine Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- UYMKPFRHYYNDTL-UHFFFAOYSA-N ethenamine Chemical group NC=C UYMKPFRHYYNDTL-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019138 food restriction Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic Secondary and tertiary amines Drugs 0.000 description 1
- 230000002496 gastric Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 230000000848 glutamatergic Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000003106 haloaryl group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000012765 hemp Nutrition 0.000 description 1
- 230000003082 hepatotoxic Effects 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 239000008079 hexane Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DCPMPXBYPZGNDC-UHFFFAOYSA-N hydron;methanediimine;chloride Chemical compound Cl.N=C=N DCPMPXBYPZGNDC-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-O hydron;urea Chemical compound NC([NH3+])=O XSQUKJJJFZCRTK-UHFFFAOYSA-O 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 229960004592 isopropanol Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 235000012766 marijuana Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000018984 mastication Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 229940113083 morpholine Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001537 neural Effects 0.000 description 1
- 230000001722 neurochemical Effects 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative Effects 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 239000012057 packaged powder Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 230000036231 pharmacokinetics Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- ZSWXMOQFFWMZQH-UHFFFAOYSA-M potassium;ditert-butyl phosphate Chemical compound [K+].CC(C)(C)OP([O-])(=O)OC(C)(C)C ZSWXMOQFFWMZQH-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 230000002633 protecting Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 230000000541 pulsatile Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- UMLDUMMLRZFROX-UHFFFAOYSA-N pyridin-2-ylboronic acid Chemical compound OB(O)C1=CC=CC=N1 UMLDUMMLRZFROX-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229910052904 quartz Inorganic materials 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 231100000197 serious side effect Toxicity 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- WSWCOQWTEOXDQX-UHFFFAOYSA-N sorbic acid Chemical compound CC=CC=CC(O)=O WSWCOQWTEOXDQX-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000707 stereoselective Effects 0.000 description 1
- 230000001954 sterilising Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 230000000576 supplementary Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000000152 swallowing Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000010874 syndrome Diseases 0.000 description 1
- 230000002194 synthesizing Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229940066769 systemic antihistamines Substituted alkylamines Drugs 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LCZVKKUAUWQDPX-UHFFFAOYSA-N tert-butyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethyl]amino]ethyl]amino]acetate Chemical compound CC(=O)OC1=CC=CC=C1CN(CC(=O)OC(C)(C)C)CCN(CC(=O)OC(C)(C)C)CC1=CC=CC=C1OC(C)=O LCZVKKUAUWQDPX-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran THF Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- 235000019505 tobacco product Nutrition 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- WXAZIUYTQHYBFW-UHFFFAOYSA-N tris(4-methylphenyl)phosphane Chemical compound C1=CC(C)=CC=C1P(C=1C=CC(C)=CC=1)C1=CC=C(C)C=C1 WXAZIUYTQHYBFW-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 201000011528 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
Disclosed are novel compounds having the structure of Formula (I) :
Description
COMPOUNDS FOR THE TREATMENT OF ADDICTION
FIELD [0001] The présent disclosure relates to novel human mitochondrial aldéhyde dehydrogenase (ALDH-2) inhibitors and their use in treating mammals for their dependence upon drugs of addiction, such as an addiction to dopamine-producing agents like cocaïne, opiates, amphétamines, nicotine, and alcohol. The disclosure further relates to methods for the use of such compounds, and to pharmaceutical compositions containing them.
BACKGROUND [0002] Today, dependence upon drugs of addiction causes major health problems worldwide. For example, alcohol abuse and alcohol dependency can cause liver, pancreatic and kidney disease, heart disease, including dilated cardiomyopathy, polyneuropathy, internai bleeding, brain détérioration, alcohol poisoning, increased incidence of many types of cancer, insomnia, dépréssion, anxiety, and even suicide. Heavy alcohol consumption by a prégnant mother can also lead to fêtai alcohol syndrome, which is an incurable condition.
Additionally, alcohol abuse and alcohol dependence are major contributing factors for head injuries, motor vehicle accidents, violence and assaults, and other neurological and other medical problems.
[0003] Addiction to nicotine is estimated by the National Institute on Drug Abuse to kill nearly 500,000 Americans every year. This total represents about 1 in 6 of ail deaths in the U.S. caused by any means, and is more than the total of deaths caused by use of alcohol, cocaïne, heroin, suicide, car accidents, fire and AIDS combined. Cigarette smoking is the most popular method of using nicotine, but there are also smokeless tobacco products such as snuff and chewing tobacco.
(0004] Nicotine addiction is linked to disease states such as leukemia, cataracts, and pneumonia; it is the cause of about one-third of ail cancer deaths, the foremost of which is lung cancer. In addition to cancer, cigarette smoking also causes lung diseases, such as bronchitis and emphysema; it exacerbâtes asthma symptoms, and is the cause of chronic obstructive pulmonary diseases in general. It is also well known that cigarette smoking increases the risk of cardiovascular diseases, including stroke, heart attack, vascular disease, aneurysm, and the like.
[0005] Another major health problem is caused by cocaïne abuse. Physical effects of cocaïne use include constricted blood vessels, dilated pupils, and increased température, heart rate, and blood pressure. A user of cocaïne can expérience acute cardiovascular or cerebrovascular emergencies, such as a heart attack or stroke, potentially resulting in sudden death. Other complications associated with cocaïne use include disturbances in heart rhythm, chest pain and respîratory failure, seizures, headaches, and gastrointestinal complications such as abdominal pain and nausea. Because cocaïne has a tendency to decrease appetite, many chronic users can become malnourished. Repeated use of cocaïne may lead to a state of increasing irritability, restlessness, and paranoïa. This can resuit in a period of full-blown paranoid psychosis, in which the user loses touch with reality and expériences auditory hallucinations. Moreover, it is well known that the concurrent abuse of nicotine, cocaïne and alcohol is common. It has been found that the combination of cocaïne and alcohol exerts more cardiovascular toxicity in humans than either drug alone.
[0006] Historically, treating chemical dependence largely involved attempts to persuade patients to discontinue use the substance voluntarily (behavioral therapy). However, cocaïne, morphine, amphétamines, nicotine, and alcohol, and other types of dopamine-producing agents are highly addictive substances, and dependence upon such drugs can be harder to break and is signifîcantly more damaging than dependence on most other addictive substances. In particular, alcohol, cocaïne, and heroin dependence are typically chronic relapsing disorders.
[0007] There has been some moderate success in providing effective treatments for tobacco addiction by the use of nicotine replacement therapy, such as nicotine gum or the nicotine transdermal patch. Additionally, antidepressants and antihypertensive drugs hâve been tried, with modest success. Attempts hâve also been made to treat tobacco addiction by persuading patients to discontinue the use of tobacco voluntarily (behavioral therapy), but this method has not proved to be very successful. Accordingly, it is clearly désirable to find a treatment for tobacco addiction that reduces or prevents the craving for nicotine that does not involve nicotine replacement therapy or the use of antidepressants and antihypertensive drugs.
[0008] Accordingly, there has been much interest in the scientifîc community in attempting to find substances that could be employed to ameliorate dependency on addictive agents.
Compounds that hâve previously been employed for the treatment of alcohol abuse include disulfiram (Antabuse™), cyanamide, naltrexone; and acamprosate.
[0009] Naltrexone, a classical opîate antagonist, appears to act by reducing alcohol craving in abstinent patients. The drug, however, is hepatotoxic and causes side-effects that often require medical intervention. Acamprosate, another approved drug, is thought to act by modulating glutamatergic Systems. It only has moderate efficacy and serious side effects that include diarrhea, allergie reactions, irregular heartbeats, and low or high blood pressure. Disulfiram, an aldéhyde dehydrogenase inhibîtor, acts by interfering with the metabolic pathway of alcohol. Normally, alcohol is metabolized to acetaldehyde, which in tum is elîminated by oxidation to acetic acid by the enzyme aldéhyde dehydrogenase. Disulfiram inhibits aldéhyde dehydrogenase and thereby prevents oxidation of alcohol-generated acetaldehyde to acetic acid. Alcohol consumption during disulfiram treatment, however, leads to the accumulation of acetaldehyde, inducing unpleasant side-effects. Because disulfiram does not reduce craving for alcohol, success with the drug dépends on a high level of patient motivation since patients who wish to drink can simply stop taking the drug. Additionally, it has been recently proposed that disulfiram can be used for the treatment of cocaïne dependency (for example, see Bonet et al., Journal of Substance Abuse Treatment, 26 (2004), 225-232).
[0010] Recently it has been shown that an isoflavone known as daidzein and structurally related dérivatives thereof are effective in suppressing éthanol intake. Daidzein is the major active component obtained from extracts of Radix puerariae, a traditional Chinese médication that suppresses éthanol intake in Syrian golden hamsters. See Keung, W. M. and Vallee, B. L. (1993) Proc. Natl. Acad. Sci. USA 90, 10008-10012 and Keung, W. M., Klyosov, A. A., and Vallee, B. L. (1997) Proc. Natl. Acad. Sci. USA 94, 1675-1679, and U.S.
Patents 5,624,910 and 6,121,010. U.S. Patents 5,624,910 and 6,121,010 disclosed ether isoflavone dérivatives of daidzein, which were shown to be effective in treating éthanol dependency.
[0011J Mechanistically, daidzein and its dérivatives were shown to be potent and sélective inhibitors of human mitochondrial aldéhyde dehydrogenase (ALDH-2), which is an enzyme involved in the major enzymatic pathway responsible for éthanol metabolism in humans. It appears préférable that daidzein analogues inhibit ALDH-2 selectively relative to the monoamine oxidase (MAO) pathway because daidzein analogues that inhibit both ALDH-2 and MAO exhibited less antidipsotropic activity. Altematively, WO 2008/014497 disclosed novel isoflavone dérivatives that are sélective ALDH-2 inhibitors with lïttle effect on the MAO pathway and, thus, are useful for the treatment of alcohol dependency.
[0012] In view of the above-indicated discoveries, a demand has emerged for additional classes of compounds that are safe and effective for the treatment of alcohol dependency, but that are structurally distinct from disulfiram, cyanamide, naltrexone; acamprosate, daidzein, and analogs thereof. Idéally, such additional classes of compounds will also be useful for the treatment of other addictive agents such as cocaïne, heroin, and nicotine, and in particular, ameliorate the tendency of abusers to relapse.
SUMMARY [0013] Surprisingly, it has now been discovered that compounds of Formula (I) as described below, although structurally unrelated to known compounds for the treatment of addictive agents, are nonetheless effective for the treatment of alcohol dependency as determined from the model studies also described herein. Further, the compounds of Formula (1) are effective in the treatment of other addictive agents such as cocaïne, heroin, and nicotine. In particular, the compounds of Formula (I) ameliorate the tendency of abusers to relapse. In certain aspects, the compounds of Formula (I) inhibit ALDH-2 selectively relative to the monoamine oxidase (MAO) pathway.
[0014] Accordingly, in certain aspects, is provided compounds of Formula (I):
wherein:
Rl is hydrogen, optionally substituted Cm alkyl, -CH2OH, -CH2OP(O)(OR20)(OR21); R2 is hydrogen, optionally substituted Cm alkyl, cycloalkyl, or halo;
each of R3, R4, R5, R6, R9, R10, R11, R12 and R13 is independently hydrogen, hydroxyl, -OP(O)(OR20)(OR21), -CH2OH, -CH2OP(O)(OR20)(OR21), optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, aminocarbonyl, acyl, acylamino, -O-(Ci to Cû-alkyl)O-(Ci to C6-alkyl), cyano, halo, -SO2NR22 * 24R25; or -NR24R25;
R7 is hydrogen or optionally substituted Cm alkyl;
21 1 -j- [ 2(1 each of R and R is independently Na , Li , K , hydrogen, Cm alkyl; or R and *71 2+ 2 1 2+
R can be combined to represent a single divalent cation Zn , Ca , or Mg .
2Ί eachofR and R is independently optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, or-NR24R2S; and each of R24 and R25 is independently chosen from hydrogen or Cm alkyl or when combined together with the nitrogen to which they are attached form a heterocycle; or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
Provtded is a compound of Formula (la):
wherein:
R1 is hydrogen, optionally substituted Cm alkyl, -CH2OH, -CH2OP(O)(OR20)(OR21), -C(O)R22, or -SO2R23;
R2 is hydrogen, optionally substituted Cm alkyl, cycloalkyl, or halo;
each of R3, R4, R5, R6, R9, R10, R11, R12 and R13 is independently hydrogen, hydroxyl, -OP(O)(OR20)(OR21), -CH2OH, -CH2OP(O)(OR20)(OR21), optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, aminocarbonyl, acyl, acylamino, -O-(C| to Ce-alkyl)O-(C[ to C6-alkyl), cyano, halo, -SO2NR24R25; or -NR24R25;
R7 is hydrogen or optionally substituted Cm alkyl;
each of R20 and R21 is independently Na+, Li+, K+, hydrogen, Cm alkyl; or R20 and R can be combined to represent a single divalent cation Zn , Ca , or Mg .
each of R22 and R23 is independently optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, or-NR24R25; and each of R24 and R25 is independently chosen from hydrogen or Cm alkyl or when combined together with the nitrogen to which they are attached form a heterocycle; or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
Also provided is a compound of formula (1b)
wherein:
R1 is hydrogen, Ck6 alkyl, -CH2OR22, -CH2OP(O)(OR20)(OR21);
Λ
R is hydrogen, cyano, Cm alkyl, C3-C6 cycloalkyl, or halo;
each of R3, R4, Rs, R6, R9, R10, R1 ’, R12 and R13 is independently hydrogen, halo, CiCi( alky, hydroxyl, or -CH2OR22;
*7
R is hydrogen or Cm alkyl;
each of R20 and R21 is independently Na*, Li+, K+, hydrogen, or Cm alkyl;
each R22 is independently hydrogen, C|-C(, alkyl, C3-C6 cycloalkyl, phenyl or benzyl; or a pharmaceutically acceptable sait, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
[0015] Also provided is a compound offormula II
wherein:
R1 is hydrogen, -CH2OH, -CH2OP(O)(OR20)(OR21), or optionally substituted Cm alkyl;
R2 is hydrogen, halo, optionally substituted lower Cm alkyl, or optionally substituted cycloalkyl;
each of R3, R4, R5, R6, R9, R10, R11, R12 and R13 is independently hydrogen, hydroxyl, -OP(O)(OR20)(OR21), -CH2OH, -CH2OP(O)(OR20)(OR21), aminocarbonyl, acyl, acylamino, -O-(C| to C6-alkyl)-O-(Ci to C&-alkyl), cyano, halo, SO2NR24R2S, -NR24R25, optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocyclyl;
R7 is hydrogen or optionally substituted Cm alkyl;
ι ι t 2Ω each of R and R is independently Na , Li , K , hydrogen, Cm alkyl; or R and
7+ 7+ 7+
R can be combined to represent a single divalent cation Zn , Ca , or Mg .
each of R22 and R23 is independently optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, or-NR24R25; and each of R24 and R25 is independently chosen from hydrogen or Cm alkyl or when combined together with the nitrogen to which they are attached form a heterocycle; or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
In certain aspects, the disclosure provides pharmaceutical compositions comprising a therapeutically effective amount of a compound of the disclosure (e.g. a compound of Formula (I) or a pharmaceutically acceptable sait, ester, prodrug, stereoisomer, solvaté, or hydrate thereof and at least one pharmaceutically acceptable carrier).
[0016] In certain aspects, is provided methods of using the compounds of Formula (1) in the treatment of addiction to a dopamine-producing agent. The method comprises administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula (I). Such diseases include, but are not Iimited to, the treatment of dependency upon cocaïne, opiates, amphétamines, nicotine, and alcohol.
[0017] Compounds of Formula (I), (la), (Ib) or (II) include, but are not Iimited to:
2.6- dichloro-4-(2-methoxyethoxy)-7V-(4-(2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide (i);
2.6- dichloro-7V-[4-(2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl]-benzamide (2);
2- chloro-3 -fluoro-Ar-(4-(2-oxo -1,2-dihydropyridin-4-yl)benzyl)benzami de (3 ) ;
2-chloro-6-methyl-?/-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (4);
2.6- dimethyl-7V-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (5);
2.6- dichloroJV-[4-(6-methyl-2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl]-benzamide (6); 2-chloro-3,6-difluoro-7V-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (7);
2.6- dichloro-7Y-(3-methyl-4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (8);
2.6- dichloro-7V-(4-(l-methyl-2-oxo-l,2~dihydropyridin-4-yl)benzyl)benzamide (9);
2.6- difluoro-JV-(4-(2-oxO“l,2-dihydropyridin-4-yl)benzyi)benzamide (10);
2-chloro-6-fluoro-jV-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (11);
2.6- dichloro JV-(2 -fluoro-4-(2 -oxo -1,2-dihydropyridi n-4-y l)benzyl)benzam ide ( 12);
2.6- dichloro-?/-(4-(5-fluoro-2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide (13); and phosphoric acid mono-(4 - {4-[ (2,6- di chloro-benzoyl ami no )-m ethyl ]-phenyl }-2-oxo-2H -pyridin-l-ylmethyl) ester (14); or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
[0018] Additional embodiments are described herein.
DETAILED DESCRIPTION [0019] Before the présent compositions and methods are described, it is to be understood that the disclosure is not limited to the particular compounds, compositions, méthodologies, protocole, cell lines, assays, and reagents described, as these may vary. It is also to be understood that the terminology used herein is intended to describe particular embodiments, and is in no way intended to limit the scope as set forth in the appended claims.
Detailed Description of Figures
Figure 1 shows significant réduction (p <0.05 versus vehicle) in alcohol self administration based on lever presses.
Figure 2 is a graphical représentation of cocaïne eue replacement study design.
Figure 3 shows significant inhibition of cocaïne eue reinstatement in rats orally administered a compound of the invention compared to vehicle.
Figure 4 shows significant inhibition of cocaïne eue reinstatement in rats oraily administered a compound of the invention compared to vehicle.
Figure 5 shows significantly reduced nicotine self administration in rats oraily administered a compound of the invention compared to vehicle.
Figure 6 shows significantly reduced nicotine self administration in rats oraily administered a compound of the invention compared to vehicle.
Figure 7 shows significantly reduced nicotine self administration in rats chronically administered oral doses of a compound of the invention compared to vehicle.
Définitions and General Parameters [0020] As used in the présent spécification, the following words and phrases are generally intended to hâve the meanings as set forth below, except to the extent that the context in which they are used ïndicates otherwise.
[00211 The term “alkyl’’ refers to a monoradical branched or unbranched saturated hydrocarbon chain having from 1 to 20 carbon atoms. This tenu is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, n-decyl, tetradecyl, and the like.
[0022] The term “substituted alkyl” refers to:
1) an alkyl group as defined above, having 1,2, 3, 4 or 5 substituents, (typically 1, 2, or 3 substituents) selected from the group consisting of alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, amînocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SOheteroaryl, -SCb-alkyl, S Cl·-aryl and -SCb-heteroaryl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1, 2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0, l or 2; or
2) an alkyl group as defined above that is interrupted by 1-10 atoms (e.g. I, 2, 3,4, or 5 atoms) independently chosen from oxygen, sulfur and NRa, where R° is chosen from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. Ail substituents may be optionally further substituted by alkyl, alkoxy, halogen, CF3, amino, substituted amino, cyano, or -S(O)nR, in which R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2; or
3) an alkyl group as defined above that has both 1,2, 3,4 or 5 substituents as defined above and is also interrupted by 1-10 atoms (e.g. 1,2, 3,4, or 5 atoms) as defined above.
[0023] The term “lower alkyl” refers to a monoradical branched or unbranched saturated hydrocarbon chain having 1, 2, 3, 4, 5, or 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, n-hexyl, and the like.
[0024] The term “substituted lower alkyl” refers to lower alkyl as defined above having I to 5 substituents (typically 1,2, or 3 substituents), as defined for substituted alkyl, or a lower alkyl group as defined above that is interrupted by 1,2, 3,4, or 5 atoms as defined for substituted alkyl, or a lower alkyl group as defined above that has both 1, 2,3,4 or 5 substituents as defined above and is also interrupted by 1,2, 3,4, or 5 atoms as defined above.
[0025] The term “alkylene” refers to a diradical of a branched or unbranched saturated hydrocarbon chain, typically having from 1 to 20 carbon atoms (e.g. 1-10 carbon atoms, or 1, 2,3,4,5 or 6 carbon atoms). This term is exemplified by groups such as methylene (-CH2-), ethylene (-CH2CH2-), the propylene isomers (e.g., -CH2CH2CH2- and-CH(CH3)CH2-), and the like.
[0026] The term “lower alkylene” refers to a diradical of a branched or unbranched saturated hydrocarbon chain, typically having 1,2, 3,4, 5, or 6 carbon atoms.
[0027] The term “substituted alkylene” refers to:
(1) an alkylene group as defined above having 1, 2,3,4, or 5 substituents (typically 1,
2, or 3 substituents) selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycioalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthîo, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryioxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SOheteroaryl, -SO2-alkyl, SO2-aryl and -SOî-heteroaryl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1,2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0,1 or 2; or (2) an alkylene group as defined above that is interrupted by 1-10 groups (e.g. 1, 2, 3, 4, or 5 groups) independently chosen from -O-, -S-, sulfonyl, -C(O)-, -C(O)O-, C(O)N-, and -NR“, where R“ is chosen from hydrogen, optionally substituted alkyl, cycioalkyl, cycloalkenyl, aryl, heteroaryl and heterocyclyl; or (3) an alkylene group as defined above that has both 1,2,3,4 or 5 substituents as defined above and is also interrupted by 1-10 groups as defined above. Examples of substituted alkylenes are chloromethylene (-CH(Cl)-), aminoethylene (-CH(NH2)CH2), methylaminoethylene (-CH(NHMe)CH2-), 2-carboxypropylene isomers(CH2CH(CO2H)CH2-), ethoxyethyl (-CH2CH2O-CH2CH2-), ethylmethylaminoethyl (CH2CH2-N(CH3)-CH2CH2-), 1 -ethoxy-2-(2-ethoxy-ethoxy)ethane (-CH2CH2OCH2CH2-OCH2CH2-OCH2CH2-), and the like.
[0028] The term “aralkyl” refers to an aryl group covalently linked to an alkylene group, where aryl and alkylene are defined herein. “Optionally substituted aralkyl” refers to an optionally substituted aryl group covalently linked to an optionally substituted alkylene group. Such aralkyl groups are exemplified by benzyl, phenylethyl, 3(4-methoxyphenyl)propyl, and the like.
[0029] The term “aralkyloxy” refers to the group -O-aralkyl. “Optionally substituted aralkyloxy” refers to an optionally substituted aralkyl group covalently linked to an optionally substituted alkylene group. Such aralkyl groups are exemplified by benzyloxy, phenylethyloxy, and the like.
[0030] The term “alkoxy” refers to the group R-O-, where R is optionally substituted alkyl or optionally substituted cycioalkyl, or R is a group -Y-Z, in which Y is optionally substituted alkylene and Z is optionally substituted alkenyl, optionally substituted alkynyl; or optionally substituted cycloalkenyl, where alkyl, alkenyl, alkynyl, cycloalkyl and cycloalkenyl are as defined herein. Typical alkoxy groups are alkyl-O- and include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, nhexyloxy, l ,2-dimethylbutoxy, and the like.
[00311 The term “lower alkoxy” refers to the group R-O- in which R is optionally substituted lower alkyl as defined above. This term is exemplified by groups such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, t-butoxy, n-hexyloxy, and the like.
[0032] The term “alkylthio” refers to the group R-S-, where R is as defined for alkoxy.
[0033] The term “alkenyl” refers to a monoradical of a branched or unbranched unsaturated hydrocarbon group typically having from 2 to 20 carbon atoms (more typically from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from 1 to 6 carbon-carbon double bonds, e.g. 1, 2, or 3 carbon-carbon double bonds. Typical alkenyl groups include ethenyl (or vinyl,
1. e. -CH=CH2), 1-propylene (or allyl, -CH2CH=CH2), isopropylene (-C(CH3)=CH2), bicyclo[2.2.1]heptene, and the like. In the event that alkenyl is attached to nitrogen, the double bond cannot be alpha to the nitrogen.
[0034] The term “lower alkenyl” refers to alkenyl as defined above having from 2 to 6 carbon atoms.
[0035] The term “substituted alkenyl” refers to an alkenyl group as defined above having 1,
2, 3, 4 or 5 substituents (typically 1, 2, or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, SO2-alkyl, SO2-aryl and -SO2-heteroaryl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1,2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
[0036] The term “alkynyl” refers to a monoradical of an unsaturated hydrocarbon, typically having from 2 to 20 carbon atoms (more typically from 2 to 10 carbon atoms, e.g. 2 to 6 carbon atoms) and having from l to 6 carbon-carbon triple bonds e.g. 1, 2, or 3 carboncarbon triple bonds. Typical alkynyl groups include ethynyl (-C^Cll), propargyl (or propynyl, -OCCHj), and the like. In the event that alkynyl is attached to nitrogen, the triple bond cannot be alpha to the nitrogen.
[0037] The term “substituted alkynyl” refers to an alkynyl group as defined above having 1, 2, 3, 4 or 5 substituents (typically 1, 2, or 3 substituents), selected from the group consisting of alkyi, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, SÜ2-alkyl, SC>2-aryl and -SCh-heteroaryl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1, 2, or 3 substituents chosen from alkyi, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyi, aryl, or heteroaryl and n is 0,1 or 2.
[0038] The term “aminocarbonyl” refers to the group -C(O)NRR where each R is independently hydrogen, alkyi, cycloalkyl, aryl, heteroaryl, heterocyclyl or where both R groups are joined to form a heterocyclic group (e.g., morpholino). Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by I, 2, or 3 substituents chosen from alkyi, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and ~S(O)nR, where R is alkyi, aryl, or heteroaryl and n is 0,1 or 2.
J0039] The term “ester” or “carboxyester” refers to the group -C(O)OR, where R is alkyi, cycloalkyl, aryl, heteroaryl, or heterocyclyl, which may be optionally further substituted by alkyi, alkoxy, halogen, CF3, amino, substituted amino, cyano, or-S(O)nRa, in which Ra is alkyi, aryl, or heteroaryl and n is 0, 1 or 2.
[0040] The term “acylamino” refers to the group -NRC(O)R where each R is independently hydrogen, alkyi, aryl, heteroaryl, or heterocyclyl. Ail substituents may be optionally further substituted by alkyi, alkoxy, halogen, CF3, amino, substituted amino, cyano, or —S(O)nR, in which R is alkyi, aryl, or heteroaryl and n is 0, 1 or 2.
[0041] The term “acyloxy” refers to the groups -OC(O)-alkyl, -OC(O)-cycloalkyl, -0C(O)-aryl, -OC(O)-heteroaryl, and -OC(O)-heterocyclyl. Unless otherwise constrained by the définition, all substituents may optionally be further substituted by l, 2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CFj, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0,1 or 2.
[0042] The term “aryl” refers to an aromatic carbocyclic group of 6 to 20 carbon atoms having a single ring (e.g., phenyl) or multiple rings (e.g., biphenyl), or multiple condensed (fused) rings (e.g., naphthyl, fluorenyl, and anthryl). Typical aryls include phenyl, fluorenyl, naphthyl, anthryl, and the like.
[0043] Unless otherwîse constrained by the définition for the aryl substituent, such aryl groups can optionally be substituted with 1,2, 3,4 or 5 substituents (typically 1,2, or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, SCL-alkyl, SO2-aryl and -SO2-heteroaryl. Unless otherwise constrained by the définition, all substituents may optionally be further substituted by 1,2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and ~S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
[0044] The term “aryloxy” refers to the group aryl-O- wherein the aryl group is as defined above, and includes optionally substituted aryl groups as also defined above. The term “arylthio” refers to the group R-S-, where R is as defined for aryl.
[0045] The term “amino” refers to the group -NH2.
[0046] The term “substituted amino” refers to the group -NRR where each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl provided that both R groups are not hydrogen, or a group -Y-Z, in which Y is optionally substituted alkylene and Z is alkenyl, cycloalkenyl, or alkynyl. Unless otherwise constrained by the définition, all substituents may optionally be further substituted by 1,2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
J0047J The term “carboxyalkyl” refers to the groups -C(O)O-alkyl, -C(O)O-cycloalkyl, where alkyl and cycloalkyl are as defined herein, and may be optionally further substituted by alkyl, alkenyl, alkynyl, alkoxy, halogen, CF3, amino, substituted amino, cyano, or-S(O)nR, in which R is alkyl, aryl, or heteroaryl and n is 0, l or 2.
[0048] The term “cycloalkyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, and the like, or multiple ring structures such as adamantanyl, and bîcyclo[2.2.1]heptane, or cyclic alkyl groups to which is fused an aryl group, for example indan, and the like.
[0049] The term “cycloalkenyl” refers to cyclic alkyl groups of from 3 to 20 carbon atoms having a single cyclic ring or multiple condensed rings and having at least one double bond and preferably from l to 2 double bonds.
[0050] The terms “substituted cycloalkyl” and “susbstituted cycloalkenyl” refer to cycloalkyl or cycloalkenyl groups having 1, 2, 3,4 or 5 substituents (typically 1,2, or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonyl ami no, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, SO2-alkyl, SO2-aryl and -SO2-heteroaryl. The term “substituted cycloalkyl” also includes cycloalkyl groups wherein one or more of the annular carbon atoms of the cycloalkyl group is a carbonyl group (i.e. an oxygen atom is oxo to the ring). Unless otherwise constratned by the définition, ail substituents may optionally be further substituted by 1,2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2.
[0051] The term “halogen” or “halo” refers to fluoro, bromo, chloro, and iodo.
[0052] The term “acyl” dénotés a group -C(O)R, in which R is hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocyclyl, optionally substituted aryl, and optionally substituted heteroaryl.
[0053] The term “alkoxycarbonylamino” refers to a group -NHC(O)OR in which R is optionally substituted alkyl.
[0054] The term “alkyl amine” refers to R-NH2 in which R is optionally substituted alkyl.
[0055] The term “dialkyl amine” refers to R-NHR in which each R is independently an optionally substituted alkyl.
[0056] The term “trialkyl amine” refers to NR3 in which R each R is independently an optionally substituted alkyl.
® Θ [0057] The term “azido” refers to a group N=N=N .
[0058] The term “hydroxyl” or “hydroxyl” refers to a group -OH.
[0059] The term “arylthio” refers to the group -S-aryl.
[0060] The term “heterocyclylthio” refers to the group -S-heterocyclyl.
[0061] The term “alkylthio” refers to the group -S-alkyl.
[0062] The term “aminosulfonyl” refers to the group -SO2NRR, wherein each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1,2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SOheteroaryl, -SOî-alkyl, SO2-aryl and -SOi-heteroaryl.
[0063] The term “aminocarbonylamino” refers to the group -NRcC(O)NRR, wherein Rc is hydrogen or alkyl and each R is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, heteroaryl and heterocyclyl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1,2, or 3 substituents selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, -SCh-alkyl, SCL-aryl and -SO2heteroaryl.
[0064] The term “heterocyclooxy” refers to the group -O-heterocyclyl.
[0065] The term “alkoxyamino” refers to the group -NHOR in which R is optionally substituted alkyl.
[0066] The term “hydroxyamino” refers to the group -NHOH.
[0067] The term “heteroaryl” refers to a group comprising single or multiple rings comprising 1 to 15 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen, and sulfur within at least one ring. The term “heteroaryl” is generic to the terms “aromatic heteroaryl” and “partially saturated heteroaryl”. The tenn “aromatic heteroaryl refera to a heteroaryl in which at least one ring is aromatic. Examples of aromatic heteroaryls include pyrrole, thiophene, pyridine, quinoline, pteridine. The term “partially saturated heteroaryl” refera to a heteroaryl having a structure équivalent to an underlying aromatic heteroaryl which has had one or more double bonds in an aromatic ring of the underlying aromatic heteroaryl saturated. Examples of partially saturated heteroaryls include dihydropyrrole, dihydropyridine, chroman, and the like.
[0068] Unless otherwise constrained by the définition for the heteroaryl substituent, such heteroaryl groupe can be optionally substituted with 1 to 5 substituents (typically 1, 2, or 3 substituents) selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl (an alkyl ester), arylthio, heteroaryl, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, aralkyl, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, -SCh-alkyl, S O?-aryl and -SCh-heteroaryl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1, 2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0,1 or 2. Such heteroaryl groups can hâve a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., îndolizinyl, benzothiazole, or benzothienyl). Examples of nitrogen heterocyclyls and heteroaryls include, but are not limited to, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, and the like as well as N-alkoxy-nitrogen containing heteroaryl compounds.
[0069] The term “heteroaryloxy” refers to the group heteroaryl-O-.
[0070] The term “heterocyclyl,” “heterocycle,” or “heterocyclîc” refers to a monoradical saturated group having a single ring or multiple condensed rings, having from l to 40 carbon atoms and from l to 10 hetero atoms, preferably 1 to 4 heteroatoms, selected from nitrogen, sulfur, phosphorus, and/or oxygen within the ring.
[0071] Unless otherwise constrained by the définition for the heterocyclîc substituent, such heterocyclîc groups can be optionally substituted with 1 to 5 substituents (typically 1, 2, or 3 substituents), selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, acyl, acylamino, acyloxy, amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxy, carboxyalkyl, arylthîo, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino, nitro, -SO-alkyl, -SO-aryl,-SO-heteroaryl, SO2-alkyl, SCh-aryl and -SOj-hetcroaryl. Unless otherwise constrained by the définition, ail substituents may optionally be further substituted by 1,2, or 3 substituents chosen from alkyl, carboxy, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, and -S(O)nR, where R is alkyl, aryl, or heteroaryl and n is 0, 1 or 2. Preferred heterocyclics include tetrahydrofuranyl, morpholino, piperidinyl, and the like.
[0072] The term “thiol” refers to the group -SH.
[0073] The term “substituted alkylthio” refers to the group -S-substituted alkyl.
[0074] The term “heteroarylthiol” refers to the group -S-heteroaryl wherein the heteroaryl group is as defined above including optionally substituted heteroaryl groups as also defined above.
[0075] The term “sulfoxide” refers to a group -S(O)R, in which R is alkyl, aryl, or heteroaryl. “Substituted sulfoxide” refers to a group -S(O)R, in which R is substituted alkyl, substituted aryl, or substituted heteroaryl, as defined herein.
|0076J The term “sulfone” refers to a group -S(O)2R, in which R is alkyl, aryl, or heteroaryl. “Substituted sulfone” refers to a group -S(O)2R, in which R is substituted alkyl, substituted aryl, or substituted heteroaryl, as defîned herein.
[0077] The term “keto” or “oxo” refers to a group -C(O)-.
[0078] The term “thiocarbonyl” refers to a group -C(S)-.
[0079] The term “carboxy” refers to a group -C(O)-OH.
[0080] “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
[0081] A “substituted” group includes embodiments in which a monoradical substituent is bound to a single atom of the substituted group (e.g. forming a branch), and also includes embodiments in which the substituent may be a diradical bridging group bound to two adjacent atoms of the substituted group, thereby forming a fused ring on the substituted group.
[0082] Where a given group (moiety) is described herein as being attached to a second group and the site of attachment is not explicit, the given group may be attached at any available site of the given group to any available site of the second group. For example, a “lower alkyl-substituted phenyl”, where the attachment sites are not explicit, may hâve any available site of the lower alkyl group attached to any available site of the phenyl group. In this regard, an “available site” is a site of the group at which a hydrogen of the group may be replaced with a substituent.
[0083] A compound of a given Formula (e.g. the “compound of Formula (1)”) is intended to encompass the compounds of the disclosure, and the pharmaceutîcally acceptable salts, pharmaceutically acceptable esters, hydrates, polymorphe, and prodrugs of such compounds. Additionally, the compounds of the disclosure may possess one or more asymmetric centers, and can be produced as a racemic mixture or as indîvidual enantiomers or diastereoisomers. The number of stereoisomers présent in any given compound of a given Formula dépends upon the number of asymmetric centers présent (there are 2 stereoisomers possible where n is the number of asymmetric centers). The individual stereoisomers may be obtained by resolving a racemic or non-racemic mixture of an intermediate at some appropriate stage of the synthesis, or by resolution of the compound by conventional means. The individual stereoisomers (including individual enantiomers and diastereoisomers) as well as racemic and non-racemic mixtures of stereoisomers are encompassed within the scope of the présent invention, ail of which are intended to be depicted by the structures of this spécification unless otherwise specifically indicated.
[0084] “Isomers” are different compounds that hâve the same molecular formula. Isomers include stereoisomers, enantiomers, and diastereomers.
[0085] “Stereoisomers” are isomers that differ only in the way the atoms are arranged in space.
[0086] “Enantiomers” are a pair of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a “racemic” mixture. The term (±) is used to designate a racemic mixture where appropriate.
[0087] “Diastereoisomers” are stereoisomers that hâve at least two asymmetric atoms, but which are not mirror-images of each other.
[0088] The absolute stereochemistry is specifïed according to the Cahn Ingold Prelog R S System. When the compound is a pure enantiomer the stereochemistry at each chiral carbon may be specifïed by either R or S. Resolved compounds whose absolute configuration is unknown are designated (+) or (-) depending on the direction (dextro- or laevorotary) that they rotate the plane of polarized light at the wavelength of the sodium D line.
[0089] Some of the compounds exist as tautomeric isomers. Tautomeric isomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imîdic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imîdic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers. Non-limiting examples of amide-comprising and imidic acid-comprising tautomers are shown below:
ΌΗ (0090] The term “therapeutically effective amount” refers to an amount that is sufficient to effect treatment, as defined below, when administered to a mammal in need of such treatment. The therapeutically effective amount will vary depending upon the subject and disease condition being treated, the weight and âge of the subject, the severity of the disease condition, the manner of administration and the like, which can readily be determined by one of ordinary skill in the art.
[0091] The term “polymorph” refers to different crystal structures of a crystalline compound. The different polymorphe may resuit from différences in crystal packing (packîng polymorphism) or différences in packing between different conformera of the same molécule (conformational polymorphism).
[0092] The term “solvaté” refers to a complex formed by the combining of a compound of Formula (1) and a solvent.
[0093] The term “hydrate” refers to tlie complex formed by the combining of a compound of Formula (I) and water.
[0094] The term “prodrug” refera to a compound of Formula (I) that includes chemical groups which, in vivo, can be converted and/or can be split off from the remainder of the molécule to provide for the active drug, a pharmaceutically acceptable sait thereof, or a biologically active métabolite thereof.
[0095] Any formula or structure given herein, including Formula (I) compounds, is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds hâve structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass nurnber. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as, but not limited to 2H (deuterium, D), 3H (tritium),1 lC, l3C, l4C, l5N, Î8F, 3tP, 32P, 35S, 36C1, and 125I. Various isotopically labeled compounds of the présent invention, for example those into which radioactive isotopes such as 3H, 13C, and l4C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, détection or imaging techniques, such as positron émission tomography (PET) or single-photon émission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
[0096] Deuterium labelled or substituted therapeutic compounds of the invention may hâve improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism, and excrétion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. An l8F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and préparations described below by substîtuting a readily available isotopically labeled reagent for a non-isotopically labeled reagent, Further, substitution with heavîer isotopes, particularly deuterium (i.e„ H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent in the compound of the Formula (I).
[0097] The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this invention any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as H or hydrogen, the position is understood to hâve hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this invention any atom specifically designated as a deuterium (D) is meant to represent deuterium.
[0098] The term “treatmenf ’ or “treating” means any administration of a compound of the invention to a mammal having a disease or susceptible to a disease for purposes including:
(i) preventing the disease, that is, causing the clinical symptoms of the disease not to develop;
(ii) inhibiting the disease, that is, arresting the development of clinical symptoms; and/or (iii) relieving the disease, i.e. causing the régression of clinical symptoms.
[0099] In many cases, the compounds of this disclosure are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups sïmilar thereto.
The term “dopamine producing agents” as used herein includes nicotine, alcohol, amphetamnines, other drugs of addiction and foods, especially sugary foods. Thus diseases related to dopamine producing agents include addiction to alcohol, cocaïne, marijuana, nicotine, food and sequela thereof e.g. obesity.
loioo] The term “pharmaceutically acceptable sait” of a given compound refers to salts that retain the biological effectiveness and properties of the given compound, and which are not biologically or otherwise undesirable. Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases inciude, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnésium salts. Salts derived from organic bases inciude, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines, dialkyl amines, trialkyl amines, substituted alkyl amines, difsubstituted alkyl) amines, tri(substituted alkyl) amines, alkenyl amines, dialkenyl amines, trialkenyl amines, substituted alkenyl amines, di(substituted alkenyl) amines, tri(substituted alkenyl) amines, cycloalkyl amines, di(cycloalkyl) amines, tri(cycloalkyl) amines, substituted cycloalkyl amines, disubstituted cycloalkyl amine, trisubstituted cycloalkyl amines, cycloalkenyl amines, di(cycloalkenyl) amines, tri(cycloalkenyl) amines, substituted cycloalkenyl amines, disubstituted cycloalkenyl amine, trisubstituted cycloalkenyl amines, aryl amines, diaryl amines, triaryl amines, heteroaryl amines, diheteroaryl amines, triheteroaryl amines, heterocyclic amines, diheterocyclic amines, triheterocyclic amines, mixed di- and tri-amines where at least two of the substituents on the amine are different and are selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, and the like. Also included are amines where the two or three substituents, together with the amino nitrogen, form a heterocyclic or heteroaryl group.
[0101] Spécifie examples of suitable amines inciude, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, tromethamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, ethylenediamine, glucosamine, N-alkylglucamines, theobromine, purines, piperazine, piperidine, morpholine, N-ethylpi péri dîne, and the like.
[0102] Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Salts derived from inorganic acids inciude hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids inciude acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like.
[0103] As used herein, “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and ail solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonie and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingrédient, its use in the therapeutic compositions is contemplated. Supplementary active ingrédients can also be incorporated into the compositions.
[0104] Where a given group (moiety) is described herein as being attached to a second group and the site of attachment is not explicit, the given group may be attached at any available site of the given group to any available site of the second group. For example, a “lower alkyl-substituted phenyl”, where the attachment sites are not explicit, may hâve any available site of the lower alkyl group attached to any available site of the phenyl group. In this regard, an “available site” is a site of the group at which a hydrogen of the group may be replaced with a substituent.
[0105] It is understood that in ail substituted groups defined above, polymers arrived at by defining substituents with further substituents to themselves (e.g., substituted aryl having a substituted aryl group as a substituent which is itself substituted with a substituted aryl group, etc.) are not intended for inclusion herein. Also not included are infinité numbers of substituents, whether the substituents are the same or different. In such cases, the maximum number of such substituents is three. Each of the above définitions is thus constrained by a limitation that, for example, substituted aryl groups are limited to -substituted aryl(substituted aryl)-substituted aryl.
Compounds of Formula (I) [0106] Nomenclature: The naming and numbering of the compounds is illustrated with a représentative compound (2):
(2) namely: 2,6-dichloro-N-[4-(2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl] -benzamide.
[0107J Accordingly, in certain aspects, is provided compounds of Formula (I):
R9 O R6
O
Formula (ia) wherein:
R‘ is hydrogen, -CH2OH, -CH2OP(O)(OR20)(OR21), or optionally substituted Cm alkyl;
R2 is hydrogen, -CN, halo, optionally substituted lower Cm alkyl, or cycloalkyl; each of R3, R4, R5, R6, R9, R10, R11, R12 and R13 is independently hydrogen, hydroxyl, aminocarbonyl, acyl, acylamino, -O-(Ci to Cû-alkyl)-O-(Ci to Cgalkyl), cyano, halo, -SO2NR24R25, -NR24R25t optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, or optionally substituted heterocyclyl;
wherein said optionally substituted alkyl, alkylene, alkynyl, alkoxy, cycloalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, or heterocyclyl are optionally substituted with one, two or three substituents independently selected from the group consisting of halo, -NO2, phenyl, heterocyclyl, heteroaryl, Cm alkyl, cycloalkyl, -N(R24)(R25), -C(O)-R24, -C(O)-OR24, -C(O)-N(R24)(R25), -CN and -O-R24;
R is hydrogen or optionally substituted Ci„6 alkyl;
each of R20 and R21 is independently Na+, Li+, K+, hydrogen, or C|-6 alkyl; or R20 and R can be combined to represent a single divalent cation Zn , Ca , or Mg“ ;
each of R22 and R23 is independently optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, or —NR24R25; and each of R24 and R25 is independently hydrogen or C|.& alkyl or when combined together with the nitrogen to which they are attached form a heterocycle; or a pharmaceutically acceptable sait, ester, or tautomer thereof.
[0108] In certain embodiments, R1 is hydrogen. In certain embodiments, R1 is Ci_6 alkyl.
In certain embodiments, R1 is methyl. In certain embodiments, R1 is -CH2OP(O)(OR20)(OR21); and each of R20 and R21 is independently Na+, Li+, K+, or hydrogen. In certain embodiments, at least one of R1, R9, R10, Ru, R12, R13 is not hydrogen. In other embodiments, at least two of R1, R9, R10, R11, R12, R13 is not hydrogen.
[0109] In certain embodiments, R2 is hydrogen. In certain embodiments, R2 is Ci-6 alkyl. In certain embodiments, R2 is methyl. In certain embodiments, R2 is selected from the group consisting of ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, and n-hexyl. In certain embodiments, R is halo. In certain embodiments, R is fluoro. In certain embodiments, R2 is chloro. In certain embodiments, R2 is bromo. In certain embodiments, R2 is iodo.
In certain embodiments, each of R3, R4, R5, R6 R9, R10, R11, R12 and R13 is independently hydrogen, hydroxyl, -OP(O)(OR20)(OR21), -CH2OH, -CH2OP(O)(OR20)(OR2‘), optionally substituted C|.6 alkyl, optionally substituted C3.8 cycloalkyl, optionally substituted C1-6 alkoxy, -O-(C| to C6-alkyl)-O-(C| to Ce-alkyl), -C(O)NH2, cyano, or halo. In certain embodiments, each of R3, R4, R5, and R6 is independently hydrogen, C1.6 alkyl, or halo. In certain embodiments, one of R3, R4, R5, or R6 is Ci-6 alkyl or halo. In certain embodiments, one of R3, R4, R5, or R6 is selected from the group consisting of ethyl, n-propyl, iso-propyl, nbutyl, iso-butyl, t-butyl, and n-hexyl. In certain embodiments, one of R3, R4, R5, or R6 is methyl. In certain embodiments, one of R3, R4, R5, or R6 îs fluoro. In certain embodiments, one of R3, R4, R5, or R6 is chloro. In certain embodiments, one of R3, R4, R5, or R6 is fluoro. In certain embodiments, one of R3, R4, R5, or R6 is iodo.
[0110J In certain embodiments, R7 is hydrogen. In certain embodiments, R7 is Cm alkyl. In certain embodiments, R7 is selected from the group consisting of ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, and n-hexyl. In certain embodiments, R7 is methyl.
[OUI] In certain embodiments, at least one of R9 and R13 is not hydrogen. In certain embodiments, at least one of R9 and R13 is halo or Cm alkyl. In certain embodiments, at least one of R9 and R13 is selected from the group consisting of ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, and n-hexyl. In certain embodiments, at least one of R9 and R13 is independently chloro, fluoro, or methyl. In certain embodiments, at least one of R9 and R13 is bromo. In certain embodiments, at least one of R9 and R13 is iodo. In certain embodiments, R9 and R13 are independently halo or Cm alkyl. In certain embodiments, R9 and R13 are independently chloro, fluoro, or methyl. In certain embodiments, R9 and R13 are chloro. In certain embodiments, R9 and R13 are methyl.
(0112] In certain embodiments, each of R10 and R12 is independently hydrogen, halo, or Cm alkyl. In certain embodiments, each of R10 and Rt2 is independently ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, t-butyl, and n-hexyl. In certain embodiments, each of R10 and R12 is independently hydrogen, chloro, fluoro, or methyl. In certain embodiments, each of R10 and R12 is independently bromo. In certain embodiments, each of R10 and R12 is independently iodo. In certain embodiments, each of R10 and R12 is independently fluoro. In certain embodiments, each of R10 and R12 is independently chloro. In certain embodiments, R10 and R12 are hydrogen.
(0113] In certain embodiments, R11 is hydrogen. In certain embodiments, R11 is -O-(Ci to C6-alkyl)-0 -(Cj to Cô-alkyl). In certain embodiments, R11 is -OCH2CH2OCH3. In certain embodiments, R11 is independently ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, t-butyl, and n-hexyl. In certain embodiments, R11 is halo. In certain embodiments, R11 is fluoro. In certain embodiments, R11 is chloro. In certain embodiments, R11 is bromo. In certain embodiments, R11 is iodo.
[0114] In certain embodiments,
is selected from the group consisting of:
[0115] In certain embodiments, R* is hydrogen, methyl, or -CH2OP(O)(OR20)(OR21); R2 is hydrogen, methyl, or fluoro; each of R3 and R4 is independently hydrogen or methyl; each of R5 and R6 is independently hydrogen or fluoro; R7 is hydrogen; R9 is hydrogen, chloro, fluoro, or methyl; R10 is hydrogen or fluoro; R11 is hydrogen or
-OCH2CH2OCH3; R12 is hydrogen or fluoro; R13 is hydrogen, chloro, fluoro, or methyl; and each of R and R is independently Na , Li , K , or hydrogen.
[0116] In certain embodiments, the structure is:
stereoisomer, mixture of stereoisomers, or tautomer thereof.
[0117] In certain embodiments, the structure is:
; or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof. The above compound is an example of a prodrug as it generates the free amide (pyridine) compound as a métabolite. One of ordinary skill in the art is able to synthesize other prodrugs of compounds of the invention based on disclosure herein and in the art.
[0118] In certain embodiments, the compound is selected from the group consisting of:
2.6- dichloro-4-(2-methoxyethoxy)-A^-(4-(2-oxo-1,2-dihydropyridin-4-yl) benzyl)benzamide (D;
2.6- dichloro-N-[4-(2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl]-benzamide (2); 2-chloro-3-fluoro-7V-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide (3);
2-chloro-6-methyl-7V-(4-(2-oxo-1,2-dihydropyridin'4-yl)benzyl)benzamide (4);
2.6- dimethyl-7V-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (5);
2.6- dichloro-/V-[4-(6-methyl-2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl]-benzamide (6);
2-chloro-3,6-difluoro-/V-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide (7);
2.6- dichloro-7V-(3-methyl-4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (8);
2.6- dichloro-7V-(4-( 1 -methyl-2-oxo-l ,2-dihydropyridin-4-yl)benzyl)benzamide (9);
2.6- difluoro-/V-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (10); 2“ChlorO“6-fluoro-7V’-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (11);
2.6- dichloro-7V-(2-fluoro-4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide (12);
2.6- dichloro-jV-(4-(5-fluoro-2-oxo-l ,2-dihydropyridin-4-yl)benzyl)benzamide (13); and phosphoric acid mono-(4- {4-[(2,6-dichloro-benzoylamino)-methyl]-phenyl}-2-oxo-2H -pyridin-l-ylmethyl) ester (14); or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
Synthcsis of the Compounds of Formula (1) [0119] Compound Préparation: The compounds can be prepared from readily available starting materials using, for example, the following general methods and procedures. It will be appreciated tliat where typical or preferred process conditions (z.e., reaction températures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures [0120] Additionally, as will be apparent to those skilled in the art, conventionai protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. The terni protecting group or PG, as used herein, is meant that a particular functional moiety, e.g., O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound. Protecting groups or PGs,as used herein, are well known in the art and include those described in detail in Protective Groups in Organic Synthesis, Fourth Ed., Greene, T.W. and Wuts, P.G., Eds., John Wiley & Sons, New York: 2007, the entire contents of which are hereby incorporated by reference, and references cited therein.
[0121] The term protecting group or PG encompasses a suitable amino protecting group that is well known in the art and includes those described in detail in Greene et al. Non-limiting examples of suitable amino protecting groups include methyl carbamate, ethyl carbamate, 9-fluorenylmethyl carbamate (Fmoc), r-butyl carbamate (BOC), and benzyl carbamate (Cbz).
[0122] The term protecting group or PG further encompasses a suitable carboxylic acid protecting group and a suitable phosphoric acid protecting group that is well known in the art and includes those described in detail in Greene et al. Non-limiting examples of suitable carboxylic acid protecting groups and suitable phosphoric acid protecting groups further include, but are not limited to, silyl—, alkyl-, alkenyl-, aryl-, and arylalkyl- protecting groups.
[0123] The term protecting group or PG further encompasses a suitable hydroxyl protecting group, that is well known in the art and includes those described in detail in Greene et al. Non-limiting examples of suitable hydroxyl protecting groups include methyl, Λ-butyl, methoxylmethyl (MOM), trimethylsilyl (TMS), triethylsilyl (TES), triisopropylsilyl (TIPS), and the like.
[0124] The term “leaving group” or “LG” as used herein, is well known among those of skill in the art as a labile substituent of a compound that is readily displaced from the compound. Leaving groups, as used herein, are described in March's Advanced Organic Chemistry, (John Wiley, and Sons, 5,b Edition, 2001), and encompass the group consisting of a halo; ORG; SRG; O(CO)RG; S(CO)R°; O(SO2)RG; OP(O)ORGORH; or N2+; wherein each RG rt and R is, independently, hydrogen, a substituted or unsubstituted, branched or unbranched, cyclic or acyclic Cμιο alkyi; a substituted or unsubstituted, branched or unbranched, cyclic or acyclic Cmo haloalkyl; a substituted or unsubstituted aryl; or a substituted or unsubstituted haloaryl. In certain embodiments, each LG is, independently, a chloro; bromo; iodo;
F
Cl
^xL.cf3
O O ; wherein each X is, independently, O or S.
|0125] The term peptide coupling agent refers to reagents used in the methods of peptide coupling that are well known to those skilled in the art as described in M. Bodansky, et al., The Practice of Peptide Synthesis, Reactivity and Structure, Concepts in Organic Chemistry, Volume 21, Second, Revised Edition, Springer-Verlag, New York, N.Y. (1994), the entire contents of which are hereby incorporated by reference. The peptide coupling agents, as used herein, that are useful in the method include, but are not limited to those disclosed in Bodansky, et al., such as C>-(7-azabenzotriazol-l-yl) -ΛζΝ,Ύ',Ύ'-tetramethyluronium hexafluorophosphate (HATU), O-benzotriazole -jV.A^jV'.Y’-tetramethyl-uronium-hexafluoro-plwsphate (HBTU), dicyclohexyl carbodiimide (DCC), diisopropyl carbodiimide (DIC). DCC/1-hydroxy benzotriazole, DCC//Vhydroxysuccinimide, l-ethyl-3-(3-dimethyllaminopropyl) carbodiimide hydrochloride EDCHCI, l-îsobutoxycarbonyl-2-isobutoxy-I,2-dihydro quinone (IIDQ), carbonyldiimidizole, /V-ethyl-5-phenylisoxazolium-3'-sulfonate (Woodward's Reagent K), benzotriazolyl-7V-hydroxytris(dimethyamino)phosphonium hexafluorophosphate (BOP), (benzotriazol-l-yloxy)tripyrrolidinophosphonîum hexafluorophosphate (PyBOP), and the like.
[0126] The term “Suzuki reaction” as used herein, is well known among those of skill in the art as and refers to a CC coupling of two reactants in which one reactant is a boronic acid or boronic ester moiety, as described by N. Miyaura and A, Suzuki; Chem. Rev.', 1995, 95, 2457-2483; and A, Suzuki, J. Organomet. Chem., 1999, 576, 147-168. Typically, the Suzuki reaction may be carried out in the presence of a palladium catalyst such as palladium(II) acetate, tetrakis(triphenylphosphine)palladium (0), palladium on activated charcoal or dichloro[l,r-bis(diphenylphosphino)ferrocene]palladium(Il), in an aprotic polar solvent (for example acetonitrile, JV.TV-dimethylformamide, dimethoxyethone or tetrahydrofuran) or a protic polar solvent (for example n-propanol, iso-propanol) or a mixture of these solvents with water. The volume of solvent used will be from approximately 3 to 30 times the quantity of boronic acid or boronic ester used. Advantageously, the palladium catalyst may contain a ligand selected from: a triphenylphosphine, a tri-o-tolylphosphine, a tri-w-tolylphosphine or a tri-p-tolylphosphine. The catalysts partîcularly preferred are palladium(II) acetate and palladium on carbon which make it possible to obtain partîcularly fast reaction kinetics. Palladium(II) acetate may be advantageously used in combination with a 2-(dicyclo hexylphosphino)biphenyl type ligand (J. P. Wolfe et al., J. Am. Chem. Soc., 1999,121, 95509561). The reaction is generally carried out in the presence of an inorganic base such as potassium carbonate, sodium carbonate, caesium carbonate, sodium hydroxi de or potassium hydroxide or in the presence of a tertiary amine such as triethylamine or diisopropylethylamine. In certain embodiments the inorganic base can be potassium carbonate or potassium hydroxide. The Suzuki reaction is preferably carried out under an inert atmosphère, for example, under an argon or nitrogen atmosphère. The reaction mixture is advantageously heated at a température in the range from 60 °C to 110 C, for 2 minutes to 24 hours. Quenching with an acidic medium, for example, in the presence of HCl, is often carried out. One skilled in the art will be able to modify these conditions, in particular by applying the variants of the Suzuki reaction which are described in the literature.
[0127] The term cyclic boronic ester moiety refers to portions of boron-comprising reactants used in Suzuki reactions such as 4,4,5,5-tetramethyl-l ,3,2-dioxa boronic ester, 4,4,5,5-tetramethyl-l,3,2-dioxaboronic ester, pinacolato dioxaboronic ester, catechol dioxaboronic ester, neopentyl glycolato dioxaboronic ester, hexylene glycolato dioxaboronic ester, [(+)-pinonediolato] dioxaboronic ester, [(-)-pinonediolato] dioxaboronic ester, diethyld-tartrate glycolato dioxaboronic ester, diethyl-l-tartrate glycolato dioxaboronic ester, diisopropyl-d-tartrate glycolato dioxaboronic ester, diisopropyl-I-tartrate-glycolato dioxaboronic ester, A/A,Ar’,Ar’-tetramethyl-d-tartaramide
-glycolato dioxaboronic ester, or A,N,;V’,7V’-tetramethyl-l -tartaramide glycolato dîoxaboronic ester.
[0128] Furthermore, the compounds may contain one or more chiral centers. Accordingly, if desired, such compounds can be prepared or isolated as pure stereoisomers, Le., as individual enantiomers or diastereomers, or as stereoisomer-enriched mixtures. Ail such stereoisomers (and enriched mixtures) are included within the scope, unless otherwise indicated. Pure stereoisomers (or enriched mixtures) may be prepared using, for example, optîcally active starting materials or stereoselective reagents well-known in the art. Alternativeiy, racemic mixtures of such compounds can be separated using, for example, chiral column chromatography, chiral resolving agents, and the like.
[0129] The starting materials for the following reactions are generally known compounds or can be prepared by known procedures or obvîous modifications thereof. For example, many of the starting materials are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wisconsin, USA), Bachem (Torrance, California, USA), EmkaChemce or Sigma (St. Louis, Missouri, USA). Others may be prepared by procedures, or obvîous modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley, and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5, and Supplémentais (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley, and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley, and Sons, 5lh Edition, 2001), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
[0130] The terms “solvent”, “inert organic solvent” or “inert solvent” mean a solvent inert under the conditions of the reaction being described in conjunction therewith [including, for example, benzene, toluene, acetonitrile, tetrahydrofuran (“THF”), dimethylformamide (“DMF”), chloroform, methylene chloride (or dichloromethone), diethyl ether, methanol, pyridine and the like], Unless specifîed to the contrary, the solvents used in the reactions are inert organic solvents.
[0131] The term “q.s.” means adding a quantity sufficient to achieve a stated function, e.g., to bring a solution to the desired volume (Le., 100%).
Synthetic Strategies [0132] The compounds of Formula (I) in which substituents R1 through R27, X1, Y1, Z1 and Z2 are as defined herein. LG is a leaving group (e.g., halo, hydroxyl, alkoxy, OSO2CF3, N2 +, etc.)·, PG is a protecting group (e.g., t-butyl, t-butyl carbamate (BOC), etc.)', and Z2 is (OH)2, (0Me)2, F3·, or (ORH)(ORJ), wherein ORH and ORJ may combine with boron to form a cyclic arylboronic ester moiety or cyclic alkylboronic ester moiety as described herein (e.g., 4,4,5,5tetramethyl-l,3,2-dioxaboronic ester, catechol dioxaboronic ester, etc.)', wherein Rl7is an optionally substituted alkylene moiety of l-6 carbon atoms.
[0133j In one embodiment, the compounds of Formula (I) may be prepared according to the synthetic sequence shown in Scheme I.
Scheme I
[0134] The compounds of Formula (I) can be prepared according to the synthetic sequence shown in Scheme I from reactants (a) and (b) that are commercially available or prepared by means well known in the art. In general, the reactants (a) and at least one molar équivalent, and preferably a slight excess (e.g., 1.2 to 1.5 molar équivalents) of (b), as shown in Scheme I, are combined under standard reaction conditions in an inert solvent, such as dimethylformamide (DMF), at a température of about 25 °C until the reaction is complété, generally about 16 hours. Standard reaction conditions may comprise the use of a molar excess of suitable base, such as sodium or potassium hydroxide, triethylamine, diisopropylethylamine, 2V-methylmorpholine (NMM), or pyridine, or in some cases where LG is hydroxyl, a peptide coupling reagent, such as O-(7-azabenzotriazol-l -yl)-N,N,Ν',N’ -tetra methyluronium hexafluorophosphate (HATU), may be used. When the reaction is substantially complété, the product is subjected, if necessary, to a deprotection sequence under standard reaction conditions (e.g., THF, CH2CI2, or the like, a molar excess of acid such as acetic acid, formic acid, trifluoroacetic acid, or the like as described herein) to yield isolated by conventional means.
[0135] Alternative methods for preparing compounds of Formula (I) are shown below in the synthetic sequences of Schemes II-V. For example, in a further embodiment, the compounds of Formula (I) may be prepared as shown in the synthetic sequence of Scheme II.
Scheme II
(c) (d)
10136] The compounds of Formula (I) can be prepared according to the synthetic sequence shown in Scheme II from the appropriate aminomethylarylboronic acid dérivative (c) and at least one équivalent, and preferably a slight excess (e.g., 1.2 to 1.5 molar équivalents), of reactant (b) under standard reaction conditions. Standard reaction conditions may comprise the use of a suitable base, or in some cases where LG is hydroxyl, at least one équivalent, and preferably a slight molar excess (e.g., 1.2 to 1.5 molar équivalents), of a peptide coupling reagent as described herein. The resulting arylboronic acid dérivative (d) and substituted pyridine (e) are then coupled under standard Suzuki reaction conditions (e.g., molar équivalents of (d) and (e) in dry DMF under argon atmosphère, at elevated températures, with approximately 5-10 molar % of palladium catalyst and a molar excess of inorganic base such as potassium carbonate, as described herein) followed, if necessary, by a deprotection sequence under standard reaction conditions (e.g., THF, CH2CI2, or the like, a molar excess of acid such as acetic acid, fonnic acid, trifluoroacetic acid, or the like as described herein) to yield the pyridin-2(17Z)-ones (g).
[0137] In another embodiment, the compounds of Formula (I) may be prepared as shown in the synthetic sequence of Scheme III.
Scheme III
[0138] The compounds of Formula (I) can be prepared according to the synthetic sequence shown in Scheme III by the coupling of an arylboronic acid dérivative, (h), and a substituted pyridine, (e), under standard Suzuki reaction conditions (e.g., molar équivalents of (h) and (e) in dry DMF, under argon atmosphère at elevated températures, with approximately 5-10 molar % of palladium catalyst and a molar excess of inorganic base such as potassium carbonate, as described herein) to yield the protected amine (i). Deprotection of (i) under standard conditions (e.g., THF, CH2CI2, or the like, a molar excess of acid such as acetic acid, formic acid, trifluoroacetic acid, or the like as described herein) yields the primary amine (j), which is combined with at least one molar équivalent, and preferably a slight excess (e.g., 1.2 to 1.5 molar équivalents), of acyl dérivative (b) under standard reaction conditions to yield the pyridin-2(l//)-ones (g). Standard reaction conditions may comprise the use of a suitable base, or in some cases where LG is hydroxyl, at least one équivalent, and preferably a slight molar excess (e.g., 1.2 to 1.5 molar équivalents), of a peptide coupling reagent as described herein.
[0139] In yet another embodiment, the compounds of Formula (I) may be prepared as shown in the synthetic sequence of Scheme IV.
Schemc IV
(m)
[0140] The compounds of Formula (I) can be prepared according to the synthetic sequence shown in Scheme IV by reacting amine (k) with at least one équivalent, and preferably a slight excess (e.g., 1.2 to 1.5 molar équivalents), of acyl dérivative (b) under standard reaction conditions to yield amide (I). Standard reaction conditions may comprise the use of a suitable base, or in some cases where LG is hydroxyl, at least one équivalent, and preferably a slight molar excess (e.g., 1.2 to 1.5 molar équivalents), of a peptide coupling reagent as described herein. Amide (1) is then coupled with pyridylboronic acid dérivative (ni) and under standard Suzuki conditions (e.g., molar équivalents of (1) and (m) in dry DMF under argon atmosphère at elevated températures, with approximately 5-10 molar % of palladium catalyst and a molar excess of inorganic base such as potassium carbonate, as described herein) to produce the substituted pyridine dérivative (f) which is converted to the pyridin-2(l/7)-ones (g) following deprotection (e.g., THF, CH2CI2, or the like, a molar excess of acid such as acetic acid, formic acid, trifluoroacetic acid, or the like as described herein).
[0141] In certain embodiments, phosphate ester dérivatives of Formula (I) may be prepared as shown below in the synthetic sequence of Scheme V.
Schcmc V
[0142] For example, phosphate ester dérivatives (r) can be prepared according to the synthetic sequence of Scheme V by the alkylation of a pyridin-2( 177)-one (g) with at least one équivalent, and preferably a slight excess (e.g., 1.2 to 1.5 molar équivalents) of linker (n), wherein R27 is an optionally substituted alkylene moiety of 1-6 carbon atoms, and at least one équivalent, and preferably a slight excess (e.g., 1.2 to 2 molar équivalents) of a suitable base such as triethyl amine, diisopropylethylamine, /V-methylmorpholine (NMM), or pyridine under standard reaction conditions to yield the alkylated pyridin-2(l/7)-one (o) dérivative which can subsequently be used to O-alkylate a molar excess (e.g., 1.2 to 5 molar équivalents) of phosphate diester (p) to yield a the corresponding phosphate triester (q). Deprotection of phosphate triester (q) under standard conditions (e.g., CH3CN/H2O or the like, a molar excess of acid such as acetic acid or the like with heating, as described herein) yields phosphate ester (r).
Scheme A
The compounds of Formula (II) can be prepared according to the synthetic sequence shown in Scheme A from reactants (I) and (2) that are commercially available or prepared by means well known in the art. In general, the reactants (1) and at least one molar équivalent, and preferably a slight excess (e.g., 1.2 to 1.5 molar équivalents) of (2), as shown in Sclieme A, are combined under standard reaction conditions in an inert solvent, such as dimethylformamide (DMF), at a température of about 25 °C until the reaction is complété, generally about 16 hours. Standard reaction conditions may comprise the use of a molar excess of suitable base, such as sodium, potassium hydroxide, triethylamine, diisopropylethylamine, N methylmorpholine (NMM), or pyridine, or in some cases where LG is hydroxyl, a peptide coupling reagent, such as O (7 azabenzotriazol 1 yl) N,N,Ν’,N' tetra methyluronium hexafluorophosphate (HATU), may be used. When the reaction is substantially complété, the product is subjected, if necessary, to a deprotectîon sequence under standard reaction conditions (e.g., THF, CH2CI2, or the like, a molar excess of acid such as acetic acid, formic acid, trifluoroacetic acid, or the like as described herein) to yield isolated by conventional means.
Scheme B
The compounds of Formula (II) may also be prepared according to the synthetic sequence shown in Scheme B from commercially available reactant (1) or prepared by means well known in the art. Formula 3 can be prepared from reactant 1 via hydrogénation. In general the reactants (1) is hydrogenated using paladium catalyst such as Pd/C, Pd(OH)2, in solvent such as éthanol or by transfer hydrogénation. Formula 3 is then coupled with commercially available reactant 2 by means well known in the art. In general, the reactants (1) and at least one molar équivalent, and preferably a slight excess (e.g., 1.2 to 1.5 molar équivalents) of (2), as shown in Scheme A, are combined under standard reaction conditions in an inert solvent, such as dimethylformamide (DMF), at a température of about 25 °C until the reaction is complété, generally in about 16 hours. Standard reaction conditions may comprise the use of a molar excess of suitable base, such as sodium or potassium hydroxide, triethylamine, diisopropylethylamine, N methylmorpholine (NMM), or pyridine, or in some cases where LG is hydroxyl, a peptide coupling reagent, such as O (7 azabenzotriazol-1-yl) N,N,Ν',N' tetra methyluronium hexafluorophosphate (HATU), may be used. When the reaction is substantially complété, the product is subjected, if necessary, to a deprotectîon sequence under standard reaction conditions (e.g., THF, CH2C12, or the like, a molar excess of acid such as acetic acid, formic acid, trifluoroacetic acid, or the like as described herein) to
The compounds of Formula (II) may be prepared according to the synthetic sequence shown in Scheme C by the coupling an arylboronic acid dérivative, (h), and a substituted pyridine, (e), under standard Suzuki reaction conditions (e.g., molar équivalents of (h) and (e) in dry DMF, under argon atmosphère at elevated températures, with approximately 5-10 molar % of palladium catalyst and a molar excess of inorganic base such as potassium carbonate, as described herein to produce the substituted pyridine dérivative (f) which is converted to the pyridin-2(lH)-ones (g) following deprotection (e.g., THF, CHoCh, or the like, a molar excess of acid such as acetic acid, formic acid, trifluoroacetic acid, or the like as described herein). Reactant pyridin-2(lH)-one (g) can be hydrogenated using palladium catalyst such as Pd/C, Pd(OH)2, in a solvent such as éthanol or by transfer hydrogénation to produce piperidone (h) which may be converted to amine (i) which in tum may be converted to formula IL reparing Compounds of formula II
Pharmaceutical Compositions [0143] In certain aspects, pharmaceutical compositions are provided comprising a therapeutîcally effective amount of a compound of Formula (I) and at least one pharmaceutically acceptable carrier.
[0144] The compounds of Formula (I) are usually administered in the form of pharmaceutical compositions. Therefore, pharmaceutical compositions are provided that contain, as the active ingrédient, one or more of the compounds of Formula (I), or a pharmaceutically acceptable sait or ester thereof, and one or more pharmaceutically acceptable excipients, carriers, including inert solid dîluents and fillers, diluents, including stérile aqueous solution and various organic solvents, perméation enhancers, solubilizers and adjuvants.
[0145J The compounds of Formula (I) may be administered alone or in combination with other therapeutic agents. Such compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington ‘s Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, PA 17,h Ed. (1985) and Modem Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).
Methods of Use [0146] In certain aspects, methods of using the compounds of Formula (I) in the treatment of addiction to a dopamine-producing agent are provided. The method comprises administering to a mammal in need thereof a therapeutically effective dose of a compound of Formula (1). Such diseases include, but are not limited to, the treatment of dependency upon cocaïne, opiates, amphétamines, nicotine, and alcohol. In certain embodiments, the compounds of Formula (I) are generally effective in the treatment of conditions that respond to the administration of ALDH-2 inhibitors. While not wishing to be bound by theory, it is believed that the compounds described herein are effective in treating addiction as a conséquence of their ability to normalize the încreased dopamine levels associated with various addictive behaviors. See, N.D. Volkow et al., Dopamine in drug abuse and addiction: results from imaging studies and treatment implications, Mol. Psychiatry 9 (2004), pp. 557569; and B.J. Everitt and M.E. Wolf, Psychomotor stimulant addiction: a neural Systems perspective, J. Neurosci. 22 (2002), pp. 3312-3320. Addictive behavior has been shown to include addiction to food particularly sugary foods. For example, in the manuscript “Evidence for sugar addiction: Behavioral and neurochemical effects of intermittent, excessive sugar intake” (Hoebel et. Al. Neurosci Biobehav Rev. 2008 ; 32(1): 20-39.), the authors wrote “What this review demonstrates is that rats with intermittent access to food and a sugar solution can show both a constellation of behaviors and parallel brain changes that are characteristic of rats that voluntarily self-administer addictive drugs. In the aggregate, this is evidence that sugar can be addictive.” [0147| Given this proposed mechanism of action, the compounds of Formula (I) are useful, for example, in the treatment of addictive and compulsive behaviors and neurological conditions associated with increased dopamine levels as described, for example, in the published U.S. patent application 20100113483. Such behaviors and conditions inciude, but are not limited to, compulsive gambling, overeating, and shopping, obsessive compulsive disorder (OCD), schizophrenia, attention déficit hyperactivity disorder, anxiety and the like. In certain embodiments, the compounds described herein hâve also been shown to be effective in treating compulsive eating disorders and obesity.
[0148] Another aspect pertains to methods of modulating (e.g., reducing) alcohol consumptîon, alcohol dependence and/or alcohol abuse for therapeutic purposes. Accordingly, in an exemplary embodiment, the modulatory method involves contacting ALDH-2 with a compound that inhibits ALDH-2. In yet another exemplary embodiment, the modulatory method involves administering a compound that increases the concentration of an aldéhyde (e.g., 5-HIAL and/or DOPAL) formed during catabolism of a neurotransmitter (e.g., 5-HT/serotonin and/or DA/dopamine). Preferably, the compound does not inhibit MAO, or inhibits MAO only to a small degree.
[0149] Another embodiment involves a method of modulating alcohol consumption for the treatment of alcohol abuse or dependence which includes the step of administering to a patient a therapeutically effective amount of a compound which inhibits ALDH-2, and/or increases the concentration of an aldéhyde (e.g., 5-HIAL and/or DOPAL) formed during catabolism of a neurotransmitter (e.g,, 5-HT and/or DA).
[0150] In certain embodiments, is provided a method of modulating alcohol consumption in a mammal comprising administering a compound of Formula (I), or a pharmaceutical composition thereof, in an amount effective to increase a concentration of an aldéhyde formed during catabolism of a neurotransmitter. In certain embodiments, the neurotransmitter is serotonin or dopamine. In certain embodiments, the aldéhyde is 5-hydroxyindoleacetaldehyde or 3,4-dihydroxyphenylacetaldehyde. In certain embodiments, the compound does not inhibit monoamine oxidase.
Tcsting [0151J Activity testing is conducted as described in those patents and patent applications referenced above, and in the Examples below, and by methods apparent to one skilled in the art. For example, as described in “The Mitochondrial Monoamine Oxidase-Aldehyde
Dehydrogenase Pathway: A Potential Site of Action of Daidzein”, J. Med. Chem. 2000, 43, 4169-4179. In general, the compounds of Formula (I) are assayed to détermine their effects on MAO and ALDH-2 independently using the membrane and lysate of a density-gradientpurified mitochondria préparation as the respective enzyme sources. The results are expressed in IC50 values.
[0152] Monitoring the influence of a compound of Formula (I) on the modulation of alcohol consumption, dependence and/or abuse in a patient can be determined by a screening assay as described herein and as described, for example, in the published U.S. patent application 20040068003. In such an assay, decreased consumption ofalcohol can be used to measure the effectiveness of compounds of Formula (I).
[0153] For example, and not by way of limitation, ALDH-2 activity is decreased in cells treated with a compound of Formula (I) which inhibits ALDH-2 and as a conséquence diverts part of 5-HT metabolic flux from the oxidative pathway, which leads to the formation of 5hydroxyindoleacetic acid (5-HIAA), to the reductive pathway, further leading to the formation of 5-hydroxytryptophol (5-HTOL). Thus, to study the effect of a compound of Formula (I) on alcohol dependence and/or abuse, for example, in a clinical trial, urine samples can be collected and levels of 5-HIAA and 5-HTOL in the samples can be determined, Decreased levels of 5-HIAA and increased levels of 5-HTOL will indicate inhibition of ALDH-2 activity. In this way, the urine [5-HTOL]/[5-HIAA] ratio can serve as a marker, indicative of the physiological response of the cells to the compound. Accordingly, this response state may be determined before, and at various points during treatment of the individual with the compound.
[0154] In one embodiment, is provided a method for monitoring the effectiveness of treatment of a subject with a compound of Formula (I) including the steps of (i) obtaining pre-administration urine samples from a subject before and after alcohol détoxification but prior to administration of the compound of Formula (I); (ii) determining the [5-HTOL]/[5HIAA] ratios in the pre-administration samples; (iii) obtaining one or more postadministration samples from the subject; (iv) determining the [5-HTOL]/[5-HIAA] ratio in the post-administration samples; (v) comparing the [5-HTOL]/[5-HIAA] ratios in the preadministration samples with that in the post administration sample or samples; and (vi) altering the administration of the compound of Formula (I) to the subject accordingly. According to such an embodiment, ALDH-2 inactivation and/or an increase in urine [5
HTOL]/[5-HIAA] ratio may be used as an indicator of the effectiveness of the compound of Formula (I), even in the absence of an observable phenotypic response.
Administration [0155| The compounds of Formula (I) are usually administered in the form of pharmaceutical compositions. Therefore provided herein are pharmaceutical compositions that contain, as the active ingrédient, one or more of the compounds of Formula (I), or a pharmaceutically acceptable sait or ester thereof, and one or more phannaceutically acceptable excipients, carriers, including inert solid diluents and fillers, diluents, including stérile aqueous solution and various organic solvents, perméation enhancers, solubilizers and adjuvants. The compounds of Formula I may be administered alone or in combination with other therapeutic agents. Such compositions are prepared in a manner well known in the pharmaceutical art (see, e.g., Remington’s Pharmaceutical Sciences, Mace Pubiishing Co., Philadelphia, PA I7,h Ed. (1985) and “Modem Pharmaceutics”, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).
[0156] The compounds of Formula (I) may be administered in either single or multiple doses by any of the accepted modes of administration of agents having sîmilar utilities, for example as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal and transdermal routes, by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, oraily, topically, as an inhalant, or via an impregnated or coated device such as a stent, for example, or an artery-inserted cylindrical polymer.
[0157] One mode for administration is parental, particularly by injection. The forms in which the novel compositions may be incorporated for administration by injection include aqueous or oil suspensions, or émulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as élixirs, mannitol, dextrose, or a stérile aqueous solution, and similar pharmaceutical vehicles. Aqueous solutions in saline are also conventionally used for injection. Ethanol, glycerol, propylene glycol, liquid polyethylene glycol, and the like (and suîtable mixtures thereof), cyclodextrin dérivatives, and vegetable oils may also be employed. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prévention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phénol, sorbic acid, thimerosal, and the like.
[0158] Stérile injectable solutions are prepared by incorporating the compound of Formula (1) in the required amount in the appropriate solvent with various other ingrédients as enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingrédients into a stérile vehicle which contains the basic dispersion medium and the required other ingrédients from those enumerated above. In the case of stérile powders for the préparation of stérile injectable solutions, the known methods of préparation include vacuum-drying and freeze-drying techniques which yield a powder of the active ingrédient plus any additional desired ingrédient from a previously sterile-filtered solution thereof.
[0159] Oral administration is another route for administration of the compounds of Formula (I). Administration may be via capsule or enteric coated tablets, or the like. In making the pharmaceutical compositions that include at least one compound of Formula (I), the active ingrédient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material (as above), which acts as a vehicle, carrier or medium for the active ingrédient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, élixirs, suspensions, émulsions, solutions, syrups, aérosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, stérile injectable solutions, and stérile packaged powders.
[0160] Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, micro crystalline cellulose, polyvinylpyrrolidone, cellulose, stérile water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnésium stéarate, and minerai oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents.
[0161] The compositions can be formulated so as to provide quick, sustained or delayed release of the active ingrédient after administration to the patient by employing procedures known in the art. Controlled release drug delivery Systems for oral administration include osmotic pump Systems and dissolutionai Systems containing polymer-coated réservoirs or drug-polymer matrix formulations. Examples of controlled release Systems are gîven in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902514; and 5,616,345. Another formulation for use in the methods employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, e.g., U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
[0162] Tire compositions are preferably formulated in a unit dosage form. The term “unit dosage forrns” refers to physically discrète units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient (e.g., a tablet, capsule, or ampoule). The compounds of Formula (I) are effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. Preferably, for oral administration, each dosage unit contains from about 10 mg to 1 g of a compound of Formula (I), more preferably from 10 to 700 mg, and for parentéral administration, preferably from 10 to 700 mg of a compound of Formula (I), more preferably about 50-300 mg. Preferred dose regimens may also include administering about 100-300 mg twice daily to a patient in need thereof. Nonetheless, it will be understood, that the amount of the compound of Formula (I) actually administered will be determined by a physician, in light of the relevant circumstances of the patient, including the condition to be treated, the chosen route of administration, the actual compound administered and its relative activity, the âge, weight, and response of the individual patient, the severity of the patient’s symptoms, and the like.
[0163] For preparing solid compositions such as tablets, the principal active ingrédient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound. When referring to these preformulation compositions as homogeneous, it is meant that the active ingrédient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forrns such as tablets, pills and capsules.
10164] Tablets or pills may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodénum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
[0165] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a face mask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.
[0166] The following examples are included to demonstrate certain embodiments. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which foliow represent techniques discovered by the inventor to fonction well in the practice , and thus can be considered to constitute modes for its practice. However, those of skill in the art should, in light of the présent disclosure, appreciate that many changes can be made in the spécifie embodiments which are disclosed and still obtain a like or similar resuit without departing from the spirit and scope.
EXAMPLES [0167] Unless otherwise stated all températures are in degrees Celsius (°C). Also, in these examples and elsewhere, abbreviations and acronyms hâve the following meanings:
Abbreviation Meaning °C Degree Celsius
5-HIAA 5-Hydroxyindoleacetic acid
5-HIAL 5-Hydroxyindoleacetaldehyde
5-HT | 5-Hydroxytryptamine (serotonin) |
5-HTOL | 5-H ydroxytryptophol |
Ae | Enzyme activities measured in the presence of a test compound |
AIDS | Acquired immune deficiency syndrome |
ALDH-2 | Human mitochondrial aldéhyde dehydrogenase |
Ao | Enzyme activities measured in the absence of a test compound |
BHA | Butylated hydroxy anisole |
BOC | tert-Butoxycarbonyl |
BOP | Benzotriazolyl-7V-hydroxytris(dimethyamino)phospho nium hexafluorophosphate |
Cbz | Benzyl carbamate |
cm | centimeter |
d | Doublet |
dd | Doublet of doublets |
DA | Dopamine |
DCC | Dicyclohexyl carbodiimide |
DCM | Di chloromethone |
DIC | Diisopropyl carbodiimide |
DIEA | A(7V-Diisopropylethylamine |
DMF | Dimethylformamide |
DMSO | Dimethylsulfoxide |
dt | Doublet of triplets |
EDTA | Ethylenediaminetetraacetic acid |
equiv/eq EtOAc | Equivalents Ethyl acetate |
EtOH | Ethanol |
FR | Fixed ratio |
g HATU | Grams O-(7-Azabenzotriazol-1 -yl)-A/ /V, - tetramethyluronium hexafluoropho sphate |
HBTU | (9-Bcnzotriazole-jV,jV,jV’,jV’-tctramethyl-uronium- |
HPLC hrs/h Hz
IC50
IIDQ ip iv
J
Kg
L
LAD
LCMS/LC-MS
LG
M m/z
M+
M+H
M+Na
MAO
Me mg
MHz min ml/mL mM mmol MOM
MS
NAD
NaPPi
NIH hex afluoro-phosphate
High-performance liquid chromatography
Hours
Hertz
The half maximal inhibitory concentration l -Isobutoxycarbonyl-2-isobutoxy-l ,2-dihydro quinone
Intraperitoneal
Intravenous
Coupling constant
Kilogram
Liter
Low alcohol-drinking rat
Liquid chromatography-mass spectrometry
Leaving group
Molar mass-to-charge ratio
Mass peak
Mass peak plus hydrogen
Mass peak plus sodium
Monoamine oxidase
Methyl
Milligram
Mégahertz
Minute
Milliliter
Millimolar
Millimole
Methoxylmethyl
Mass spectroscopy
Nicotinamide Adenine Dinucleotide
Sodium pyrophosphate
National Institute of Health
NMM | ïV-Methyl morpho li ne |
NMR | Nuclear magnetic résonance |
NP | Alcohol non-preferring rat |
OCD | Obsessive compulsive disorder |
PG | Protecting group |
Ph | Phenyl |
PyBOP | (Benzotriazol-1 -yloxy)tripyrrolidinophosphonium hexafluorophosphate |
q.s. RT/rt/R.T | Quantity sufficient to achieve a stated function Room température |
s | Second |
s | Singlet |
SA | Self-administration |
SC | Subcutaneous |
SEM | Standard error of means |
t | Triplet |
TEA | Triethylamine |
TES | Triethylsilyl |
TFA | Trifluoroacetic acid |
THF | Tetrahydrofuran |
TIPS | Triisopropylsilyl |
TKK | TKK buffer |
TLC | Thin layer chromatography |
TMS | Trimethylsilyl |
TO | Time out |
Tris | tris(hydroxymethyl)aminomethone |
δ | Chemical shift |
pg μΙ7 μΐ μΜ μιηοΙ | Microgram Microliter Micromolar Micromole |
Examplc 1
Thepréparation of 2,6-dichloro-4-(2-methoxyethoxy)-N-(4-(2-oxo-l,2 -dihydropyridin-4yl)benzyl)benzamide (1) according to the synthetic route of Scheme I:
Scheme VII
Step I — The préparation of2,6-dichloro-4-(2-methoxyethoxy)benzaldehyde:
[0168] 2,6-Dichloro-4-hydroxybenzaldehyde (0.5g, 2.62 mmol), l-bromo-2 -methoxyethone (0.3 mL), sodium iodide (0.4g, 0.4 mmol) and potassium carbonate (0.9 g,
6.55 mmol) were added in DMF (5 mL) and heated at 100 °C for 1 h under stirring. When the reaction was done, the reaction mixture was diluted with EtOAc and extracted three times with water. The organic phase was dried over magnésium sulfate, filtered and concentrated in vacuum. The resultîng solid was purified by normal phase chromatography (hexanes: EtOAc 3:1) to afford 2,6-dichloro-4-(2-methoxyethoxy) benzaldehyde.
Step 2 — The préparation of 2,6-dichloro-4-(2-methoxyethoxy)benzoic acid:
[0169] 2,6-Dichloro-4-(2-methoxyethoxy)benzaldehyde (0.5g, 2.0 mmol) in acetone (20 mL) were cooled down in ice bath and then potassium permanganate (0.47 g, 3.0 mmol) in water (5 mL) was added slowly under vigorous stirring. The reaction mixture was warmed up slowly to room température and reacted over 24 h. The reaction mixture was filtered through celite and washed with acetone. The organic phase was evaporated and then re-dissolved in EtOAc to be extracted with IN HCl aqueous solution. The organic phase was dried over magnésium sulfate, filtered and concentrated in vacuum to afford the compound 2,6-dichloro4-(2-methoxyethoxy)benzoic acid.
Step 3 - The préparation ofN-(4-bromobenzyl)-2,6-dichloro-4-(2-methoxyethoxy) benzamide:
(0170] 2,6-Dichloro-4-(2-methoxyethoxy)benzoic acid (0.1g, 0.23mmol), (4-bromophenyl) methanamine hydrochloride (0.1 g, 0.27 mmol), 2-(lH-7-azabenzotriazol -l-yl)-l, 1,3,3tetramethyl uronium hexafluorophosphate methanaminium (HATU) (0.17 g, 0.27 mmol), and triethylamine (0.15 mL, 0.7 mmol) were combined in DMF (3 mL) and then stirred at room température until reaction was completed. The reaction mixture was diluted with ethyl acetate and washed with water and twice with a saturated sodium bicarbonate solution. The organic phase was dried over magnésium sulfate, filtered and concentrated in vacuum. The solid resultîng was used for next step without further purification.
Step 4 - Thepréparation of2,6-dichloro-4-(2-methoxyethoxy)-N-(4-(2-oxo-l,2 -dihydropyridin-4-yl)benzyl)benzamide:
[0171] N-(4-Bromobenzyl)-2,6-dichloro-4-(2-methoxyethoxy)benzamide (0.11 g, 0.25 mmol), 2-tert-butoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.085 g, 0.3 mmol), césium carbonate (0.2 lg, 0.75 mmol), and [1,1’ Bis(diphenyl phosphino(ferrocene]dichloropalladium(II) (15 mg, 0.025 mmol) were dissolved in degassed DMF (3 mL) and H2O (1.5 mL). The reaction mixture was degassed by bubbling nitrogen through for 15 min and then heated in the microwave at 85 °C for 20 min, The reaction mixture was diluted with EtOAc and extracted with water. The organic phase was dried over magnésium sulfate, filtered and concentrated in vacuum. The crude product was suspended in hot acetonitrile and the solids filtered out to hâve the pure compound N-(4-(2-tertbutoxypyridin-4-yl)benzyl)-2,6-dichloro-4-(2-methoxy ethoxy)benzamide that was used for next step without further purification.
[0172] Compound N-(4-(2-tert-butoxypyrî d in-4-yl )b enzyl)-2,6-dichloro-4- (2-m ethoxy ethoxy)benzamide was re-dissolved in DCM (2 mL) and trîfluoroacetic acid (2 mL) and stirred at room température for 1 h. after the reaction was done it was concentrated in vacuum and then purified by reverse phase chromatography to afford 2,6-dichloro-4-(2 -methoxyethoxy)-N-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide.
[0173] MS found for C22H20CI2N2O4 as (M+H)+ 448.32 'H NMR (400MHz, dmso-d6)\ ’HNMR (DMSO) δ: 11.58 (s, 1 H), 9.10 (t, J=6.0Hz, 1 H), 7.66 (d, J=8.4Hz, 2H), 7.46 (d, J=8.0Hz, 2H), 7.4 (s, 1 H), 7.12 (s, 2H), 6.56 (s, IH), 6.48 (d, J=5.2Hz, IH), 4.47 (d, J=6.0Hz, 2H), 4.16 (t, J=4.4Hz, 2H), 4.62 (t, J=4.4Hz, 2H), 3.27 (s, 3H).
Example 2
Thepréparation of 2t6-dichloro-N-[4-(2-oxo-l,2-dihydro-pyridin~4-yl)~benzyll -benzatnide (2) according to the synthetic route of Scheme II:
HCl- Η2Ν·^γ%
HCOOH, DCM
Pd(dppf)CI2, K2CO3,
Step 1 — The préparation of 4-[(2,6-dichloro-benzoylamino)methyl]phenylboronic acid
Cl O
B(OH)2 [0174] 4-(Aminomethyl)phenylboronic acid hydrochloride (5 g, 26.7 mmol) was dissolved in 25 mL water. 16 mL 50% aqueous KOH solution was added followed by 2,615 dichlorobenzoyl chloride (6.7 g, 32 mmol). The mixture was stirred rapidly at room température over night. Acidification with IN HCl gave a thick, white precipitate which was filtered, washed with water and dried giving 4-[(2,6-dichIoro-benzoylamino) methyljphenylboronic acid as a white powder in quantitative yield.
Step2 — The préparation ofN-[4-(2-tert-butoxy-pyridin-4-yl)-benzyl]-2,6-dichloro
-benzamide
[0175] 4-[(2,6-Dichloro-benzoylamino)methyl]phenylboronic acid (5 g, 15.4 mmol), potassium carbonate (5 g), and [Ι,Γ bis(diphenylphosphino)ferrocene] dichloropalladium (II) (0.56g, 0.77 mmol) were combined in a round bottom flask. 4-Bromo-2-(t-butoxy) pyridine (3.55g, 15.4 mmol) was dissolved in 20 mL DMF and added to the flask under stirring. The flask was flushed with nitrogen and 10 mL water was added. The reaction mixture was stirred at 70 °C for two hours. After cooling the mixture was poured into 300 mL ethyl acetate and washed with water and brine. The organic phase was dried with magnésium sulfate and evaporated under vacuum. The crude N-[4-(2-tert-butoxy-pyridin -4-yl)-benzyl]-2,6-dichloro-benzamide was further purified by silica gel chromatography (eluent: hexone/ethyl acetate 1:1).
Step 3 — The préparation of 2,6-Dichloro-N-[4-(2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl] -benzamide
[0176] V-[4-(2-/er/,-Butoxy-pyridin-4-yl)-benzyl]-2,6-dichloro-benzamidc was dissolved în 30 mL dichloromethone and 12 mL of 98% formic acid. The mixture was stirred at 40 °C for three hours after which the volatile components were evaporated under vacuum. The residue was triturated with ethyl acetate, filtered, washed with ethyl acetate and dried gîving 2,6di chloro-A- [4-(2-oxo-1,2-dihydro-pyri din-4-yl)-b enzyl]
-benzamide (4.34 g, 75.5% yield over two steps) as white powder. C19H14CI2N2O2; MS m/z\ 373 (MH+) ‘H NMR(DMSO-d6): δ 11.56 (s, IH), δ 9.21 (t, J=5.6Hz, IH), δ 7.67 (d, J= 8.0Hz, 2H), δ 7.46 (m, 6H), δ 6.57 (d, J=1.2Hz, IH), δ 6.49 (dd, J=6.8Hz, J’=1.6Hz, IH), δ
4.50 (d, J=6.0Hz, 2H.
Example 3
A. The préparation of 2-chloro-3-fluoro-N-(4-(2-oxo~l,2-dihydropyridin-4-yl)benzyl) benzamide (3) according to the synthetîc route ofScheme Iii:
B(OH)2
Scheme IX
O'Bu
Pd(dppf)CI2, K2CO3,
Toluene/H2O/EtOH 2:1:1
BocHN
70°C
Step 1 - The préparation of 4-(4-(aminomethyl)phenyl)pyridin-2(lH)-one [0177] To a solution of 4-((tert-butoxycarbonylamino)methyl)phenylboronic acid (1 g, 3.98 mmol), potassium carbonate (1.1g, 7.96 mmol), 4-Bromo-2-(t-butoxy)pyridine (1.1g, 4.78 mmol) in degassed toluene/EtOH/water (2:1:1 ) (6 mL) was added [1,1 '-Bis (diphenylphosphino)ferrocene]dichloropalladium (II) (0.14 g, 0.199 mmol). The reaction mixture was then heated in the microwave at 75 °C for 30min. After cooling the mixture, it was purified by silica gel chromatography (eluent: CFfeCh/ethyl acetate 95:5) to yield tertbutyl 4-(2-tert-butoxypyridin-4-yl)benzylcarbamate (1). MS found for CîjHîgNiOî as (M+H)+ 356.8. To the above Boc protected compound (462 mg, 1.3 mmol) in CH2CI2 (3 mL), 4.0 M HCl dioxane (1.6 mL, 6.5 mmol) was added and stirred at rt for lh. The reaction mixture was then dîluted with ether and the resulting solids were filtered and washed with ether and dried to give 4-(4-(aminomethyl)phenyl)pyridin-2(lH) -one (2) as hydrochloride sait. C12H12N2O201.0 (M+l).
Siep 2 - Thepréparation of 2-chloro-3-fluoro-N-(4-(2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide [0178] To the above amine (50 mg, 0.212 mmol), 2-chloro-3-fluorobenzoic acid (48 mg, 0.276 mmol), HATU (121 mg, 0.318 mmol), in DMF (1 mL) was added NMM (0.06 mL, 0.53 mmol) and stirred at rt for 16 hours. The reaction mixture was diluted with water and acetonitrile and the resulting solid was filtered and washed with ether and dried to give 2chloro-3-fl uoro-jV-(4-(2-oxo -1,2-dihydropyri di n-4-yl)b enzyl)benzam ide.
[0179] MS found for C19H14CIFN2O2 as (M+H)+ 357.1 ’H NMR (400MHz, dmso-d6): δ: 11.56 (br, IH), 9.13 (t, .7=6.0 Hz, IH), 7.68 (d, .7=8.0 Hz, 2H), 7.50-7.42 (m, 4H), 7.32 (d, J=7.2 Hz, 2H); 6.56 (s, IH), 6.50 (d, 7=7.2 Hz, IH); 4.49 (d, .7=6.0 Hz, 2H).
B. Thepréparation of additional compounds of Formula (I) according to the synthetic route of Scheme III:
Thepréparation n of2-chloro-6-methyl-N-(4-(2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide (4):
[0180] Compound (4) was prepared using a similar procedure as that described for Compound (3) with the appropriate starting materials. MS found for C20H17CIN2O2 as (M+H)+ 353.1 'H NMR (400MHz, dmso-d6)·. Ô: 11.54 (br, IH), 9.04 (t, 7=6.0 Hz, 1 H), 7.68 (d,7=8.0 Hz, 2H), 7.47 (d, 7=8.0 Hz, 2H), 7.45 (d, 7=7.2 Hz, IH), 7.30-7.19 (m, 3H), 6.56 (s, IH), 6.50 (d, 7=7.2 Hz, IH); 4.49 (d, 7=6.0 Hz, 2H); 2.22 (s, 3H).
The préparation of 2,6-dimethyl-N-(4-(2~oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (5):
[0181] Compound (5) was prepared using a similar procedure as that described for Compound (3) with the appropriate starting materials. MS found for C21H20N2O2 as (M+H)+
353.1 'H NMR (400MHz, dmso-d6): δ: 11.55 (br, IH), 8.86 (t, 7=6.0 Hz, IH), 7.68 (d,7=8.0
Hz, 2H), 7.45-7.40 (m, 3H), 7.16 (t, J=8.0 Hz, IH), 7.02 (d, 7=7.2 Hz, 2H), 6.56 (s, IH), 6.50 (d, 7=7.2 Hz, IH); 4.47 (d, 7=6.0 Hz, 2H); 2.18 (s, 6H).
The préparation of 2,6-Dichloro-N-[4-(6-methyl-2-oxo-l,2~dihydro-pyridin-4-yl)-benzyl] benzamide (6):
[0182] Compound (6) was prepared using a similar procedure as that described for Compound (3) with the appropriate starting materials. ’H-NMR (DMSO) ô: 11.55 (br, IH), 9.21 (t, J=6.0Hz, IH), 7.65 (d, J=8.0Hz, 2H), 7.52-7.40 (m, 5H), 6.38 (s, IH), 6.35 (s, IH),
4.50 (d, J=6.0Hz, 2H), 2.21 (s, 3H). MS: 387/389 (MH+).
Example 4
A. The préparation of 2-chloro-3,6-difluoro~N-(4~(2-oxo-l,2-dihydropyriditi-4-yl) benzyl)benzamide (7) according to the synthetic route of Schente IV:
Scheme X
Step 1 - Thepréparation ofN-(4-bromobenzyl)-2-chloro-3,6-difluorobenzamide:
[0183] (4-Bromophenyl) methanamine hydrochloride (0,5 g, 2.25 mmol), 2-chloro-3,6 -difluorobenzoic acid (0.52 g, 2.7 mmol), 2-(lH-7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyl uronium hexafluorophosphate methanaminium (HATU) (1.2g, 2.7 mmol), andAJVdiisopropyl-ethylamine (1,17 mL, 6.75mmol) were combined in DMF (6 mL) and then stirred at room température for 1 h. The reaction mixture was diluted in ethyl acetate and washed once with water and twice with an aqueous saturated sodium bicarbonate solution. The organic phase was dried over magnésium sulfate, fiitered and concentrated in vacuum. The crude product was suspended in hot acetonitrile and then fiitered to hâve the pure compound N-(4-bromobenzyl)-2-chloro-3,6-difluorobenzamide.
Step 2 - Thepréparation of2-tert-butoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl) pyridine:
[0184] 4-Bromo-2-tert-butoxypyridine (1.0 g, 4.34 mmol), pinacoldiboron (1.32 g, 5.2 mmol), potassium acetate (1.28 g, 5.2 mmol) and [1,1 ’ Bîs(diphenylphosphino(ferrocene] dichloropalladium(H) (0.318 g, 0.52 mmol) were dissolved in degassed DMF (8 mL) and H2O (4 mL). This mixture was heated at 85 °C for 20 min. The reaction mixture was extracted with EtOAc in présence of water. The organic phase was dried over magnésium sulfate, fiitered and concentrated in vacuum. The solids were purified by column (hexone: EtOAc, 3:1) to yield the pure compound 2-tert-butoxy-4-(4,4,5,5-tetramethyl-l,3,2 -di oxaborolan-2-yl)pyridine.
Step 3 — The préparation of N-(4-(2-tert-butoxypyridin-4-yl)benzyl)-2-chloro~3,6
-difl uorobenzamide:
[0185] Compound 7V-(4-bromobenzyl)-2-chloro-3,6-difluorobenzamide (0.2 g, 0.55 mmol), 2-tert-butoxy-4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)pyridine (0.17 g, 0.6 mmol), Cs2CO3 (0.54 g, 1.65 mmol), and [1,1 ’ Bis(diphenyl phosphino (ferrocene]dichloro palladium (II) (40 mg, 0.05 mmol) were dissolved in degassed DMF (3 mL) and H2O (1.5 mL). The reaction mixture was degassed again by bubbling nitrogen through for 15 min and then heated in the microwave at 85 °C for 20min, The reaction mixture was diluted with EtOAc and extracted two times with water. The organic phase was dried over magnésium sulfate, filtered and concentrated in vacuum. The crude product was heated in acetonitrile and the solids filtered to hâve the pure compound A-(4-(2-tert-butoxypyridin-4-yl)benzyl)-2-chloro3,6-difluorobenzamide that was used for next step without further purification.
[0186] The compound N-(4-(2-tert-butoxypyridin-4-yl)benzyl)-2-chloro-3,6difluorobenzamide was re-dissolved in DCM (2 mL) and trifluoroacetic acid (2 mL) and stirred at room température for 1 h. The reaction mixture was concentrated in vacuum and then purified by reverse phase chromatography to afford 2-chloro-3,6-difluoro-7V-(4 -(2-oxo1,2-dihydropyri din-4-yl)benzyl )b enzamide.
[0187] MS found for C19HI3C1F2N2O2 as (M+H)+ 377.16 'H NMR (400 MHz, dmso-d6): lH-NMR (DMSO) δ: 11.65 (s, IH), 9.36 (t, J=6.0Hz, IH), 7.69 (d,./=8.4Hz, 2H), 7.58-7.52 (m, IH), 7.46-7.37 (m, 4H), 6.61 (s, IH), 6.55-6.53 (m, IH), 4.52 (d,./=5.6Hz, 2H).
B. Thepréparation of additional compounds of Formula (I) according to the synthetic route of Scheme II·':
Thepréparation of 2,6-dichloro-N-(3-methyl-4-(2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide (8):
Cl .O
Step 1 — The préparation ofN-(4-bromo-3-methylbenzyl)-2,6-dichlorobenzamide:
[0188] 4-Bromo-3-methylphenyl)methanamine (0.1 g, 0.5 mmol), 2,6-dîchlorobenzoic acid (0.11 g, 0.6 mmol), 2-(17f-7-azabenzotriazol-l-yl)-l,l,3,3-tetramethyl uronium hexafluorophosphate methanaminium (HATU) (0.23 g, 0.6 mmol), and N,N
Diisopropylethylamine (0.2 mL, l .25 mmol) were combined in DMF (3 mL) and then stirred at room température until reaction was completed. Compound was precipitated by the addition of water and aqueous saturated solution of sodium bicarbonate. The précipitâtes were collected by filtration and then re-suspended in hot acetonitrile. When the solution was cooled down the solids were collected by filtration to hâve the pure compound N-(4 -bromo3-methylbenzyl)-2,6-dichlorobenzamide that was used for next step without further purification.
Step 2— The préparation of2,6-dichloro-N-(3~methyl-4~(2-oxo-l,2-dihydropyridin-4-yl) benzytybenzamide [0189] N-(4-Bromo-3-methylbenzyl)-2,6-dichlorobenzamide (0.13 g, 0.35 mmol), 2-oxo -l,2-dihydropyridin-4-yIboronic acid (0.053 g, 0.39 mmol), césium carbonate (0.34 g, 1.05 mmol), [1,1 * Bis(diphenylphosphino(ferrocene]dichloropalladium(II) (25 mg, 0.035 mmol) were dissolved in degassed DMF (3 mL) and H2O (1.5 mL). The reaction mixture was degassed again by bubbling nitrogen through for 15 min then heated in the microwave at 85 °C for 20 min. The reaction mixture was diluted with EtOAc and extracted three times with water. The organic phase was dried over magnésium sulfate, filtered and concentrated in vacuum. The resulting solid was purifîed by reverse phase chromatography to afford 2,6dichloro-A-(3-methyl-4-(2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide.
[0190] MS found for C2oH16C12N202 as (M+H)+ 389.13 ‘H NMR (400MHz, dmso-d6)'. lHNMR (DMSO) S: 11.62 (s, 1H), 9.18 (t, J=6.4Hz, 1 H), 7.51-4.49 (m, 2H), 7.44-7.37 (m, 2H), 7.3 (s, 2H), 7.26 (d, J=7.6Hz, 1 H), 7.17 (d, J=7.6Hz, 1 H), 6.18 (s, 1 H), 6.15-6.13 (m, 1 H), 4.46 (d, J=6.0Hz, 1H), 2.24 (s, 3H).
The préparation of 2,6-dichloro-N-(4-(l-methyl-2-oxo-l,2-dihydropyridin-4-yl) benzytybenzamide (9):
Cl
O
O [0191] Compound (9) was prepared using a similar procedure as that described for
Compound (8) with the appropriate starting materials. MS found for C2oHi6CI2N202: 387 (MH+); ’H NMR (DMSO-d6): δ 9.21 (t, J=6.0Hz, 1H), δ 7.74(d, J= 7.2Hz, 1H), δ 7.69 (d, J=
8.4Hz, 2H), δ 7.46 (m, 5H), δ 6.66 (d, J=2.0Hz, IH), δ 6.56 (dd, J=6.8Hz, J’=2.0Hz, IH), δ
4.50 (d, J=5.6Hz, 2H), δ 3.43 (s, 3H).
Thepréparation of 2,6-difluoro-N-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (10):
F O
O [0192] Compound (10) was prepared using a similar procedure as that described for
Compound (8) with the appropriate starting materials. MS found for C^Hi^NzOh: 341 (MH+); ‘H NMR (DMSO-d6): δ 11.56 (s, IH), δ 9.29 (t, J=6.0Hz, IH), δ 7.68 (d, J= 8.0Hz, 2H), δ 7.51 (m, IH), δ 7.42 (m, 3H), δ 7.17 (m, 2H), δ 6.57 (d, J= 1.2Hz, IH), δ 6.49 (dd, J=6.8Hz, J’=1.6Hz, IH), δ 4.50 (d, J=6.0Hz, 2H).
Thepréparation of 2-chloro-6-fluoro-N-(4-(2-oxo-l, 2-dihydropyridin-4-yl) benzyl)benzamide (11):
[0193] Compound (11) was prepared using a similar procedure as that described for Compound (8) with the appropriate starting materials. MS found for CigHuCIFNiCb: 357 (MH+); 'H NMR (DMSO-d6): δ 11.56 (s, 1 H), δ 9.29 (t, J=4.8Hz, 1 H), δ 7.70 (d, J= 7.6Hz,
2H), δ 7.41 (m, 6H), δ 6.59 (s, IH), ô 6.52 (d, J=6.4Hz, IH), δ 4.53 (d, J=5.6Hz, 2H).
The préparation of 2,6-dichloro-N-(2-fluoro-4-(2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide (12):
[0194J Compound (12) was prepared using a similar procedure as that described for
Compound (8) with the appropriate starting materials. MS found for CjtjHiaChFNjCh: 391 (MH+); *H NMR (DMSO-d6): δ 11.62 (s, IH), δ 9.23 (t, J=5.6Hz, IH), δ 7.57 (m, 3H), δ 7.50 (m, 2H), ô 7.43 (m, 2H), Ô 6.63 (d, J=1.2Hz, IH), δ 6.52 (dd, J=6.8Hz, J’=1.6Hz, IH), δ 4.51 5 (d, J=6.0Hz, 2H).
The préparation of 2,6-dichloro-N-(4-(5-fluoro-2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide (13):
Cl O
O [0195] Compound (13) was prepared using a similar procedure as that described for
Compound (8) with the appropriate starting materials. MS found for CigHnChFNîOï: 391 (MH+); 'H NMR (DMSO-d6): δ 11.27 (s, 1 H), δ 9.23 (t, J=6.0Hz, IH), δ 7.80 (d, >4.0Hz,
IH), δ 7.50 (m, 7H), ô 6.53 (d, J=6.4Hz, IH), δ 4.52 (d, J=6.0Hz, 2H).
Example 5
The préparation of phosphorie acid mono-(4-{4-[(2,6~dichloro-benzoylamino)-methyl] ~phenyl}-2-oxo-2H-pyridin-l-ylmethyl) ester (14) according to the synthetic route of
Scheme V:
Scheme XI
70°C, 4h
Step 1 — The préparation of 2,6-dichloro-N-[4-(l-chloromethyl-2-oxo-l,2-dihydro -pyridin-4yl)-benzyl] -benzami de [0196] 2,6-Dichloro-/V-[4-(2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl]-benzamide (1.62g, 4.34 mmol) was suspended in 15 mL dichloromethone. Chloromethylchloroformate (0.672g, 5.21 mmol) was added followed by 3 mL DMF. The mixture was stirred at room température for five hours. After diluting with 200 mL ethyl acetate, the organic phase was washed with saturated, aqueous sodium bicarbonate solution and brine, dried with magnésium sulfate and evaporated under vacuum. The crude 2,6-dichloro-/V-[4-(l -chloromethyl-2-oxo-l,2-dihydropyridin-4-yl)-benzyl]-benzamide was used in the following step without further purification.
Step 2 — The préparation ofphosphoric acid di-tert-butyl ester 4-{4-[(2,6-dichloro -benzoylaminofm ethyl] -phenyl}-2-oxo-2H-pyridin-l-ylmethyl ester [0197] 2,6-Dichloro-A-[4-(l-chloromethyl-2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl] -benzamide from the previous step was dissolved in 50 mL DMF. Potassium carbonate (lg) was added followed by potassium di(t-butyl)phosphate (2g) and tetrabutylammonium iodide (50mg). The mixture was stirred at 70 °C for four hours after which it was poured into 300 mL ethyl acetate. The organic phase was washed with water and brine, dried with magnésium sulfate and evaporated under vacuum. The crude product was further purified by silica gel chromatography (eluent: ethyl acetate), giving phosphoric acid di-tert-butyl ester 4-{4-[(2,6dichloro-benzoylamino)-methyl]-phenyl} -2-oxo-2H-pyridin-l-ylmethyl ester as a colorless oil which slowly crystallized.
Step 3 — Thepréparation of phosphoric acid mono-(4-{4~[(2,6-dichloro-benzoylamino) -methyl]-phenyl}-2-oxo-2H-pyridin-î-ylmethyl) ester [0198] Phosphoric acid di-tert-butyl ester 4-{4-((2,6-dichloro-benzoyiamino)-methyl] -phenyl}-2-oxo-2H-pyridin-l-ylmethyl ester from the previous step was dissolved in 20 mL acetonitrile, 20 mL acetic acid and 20 mL water, and heated at 70 °C for four hours. Ail volatile components were evaporated under vacuum and the residue was dissolved in 10 mL DMF. Slow addition of acetonitrile (~60 mL) precipitated the product which was filtered, washed with more acetonitrile and dried, giving phosphoric acid mono-(4-{4 -[(2,6-dichlorobenzoylamino)-methyl]-phenyl}-2-oxo-2H-pyridin-l-ylmethyl) ester (1.17g, 56% over three steps) as a white powder.
101991 ‘H-NMR (DMSO) δ: 9.23 (t, J=6.2Hz, 1H), 7.73 (d, J=8.4Hz, 2H), 7.71 (d, J=8.4Hz, 1H), 7.52-7.40 (m, 5H), 6.72 (d, J=1.6Hz, 1H), 6.65 (dd, J=7.2Hz, J=1.6Hz, 1H), 5.61 (d, J=9.6Hz, 2H), 4.52 (d, J=6.4Hz, 2H). MS: 483/485 (MH +).
Examplc 6
2,6-dimethyl-N-(4-(2-oxopiperidin-4-yl)benzyl)benzamide
To a solution of 2,6-dimethyl-N-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide (see compound 5 of example 3B) in ethanoi/methanol (5:1), 10%Pd/C was added and the mixture was hydrogenated (1 atm) at 23 °C for 12 hours. The catalyst was filtered through celite pad and washed with methanol. Filtrate and washings were combined and the solvent was then concentrated and chromatographed (SiO2, 3-15% EtOAc/MeOH) to provide the title compound. MS found for C21H24N2O2 as (M+H)+ 337.1 'H NMR (400MHz, dmso-d(f. δ: 8.76 (t, J = 5.6 Hz, 1H); 7.52 (brs, 1H), 7.27-7.14 (m, 4H); 7.13-6.99 (m, 3H); 4.40 (d, J = 6.4 Hz, 2H); 3.23-3.16 (m, 2H); 3003-2.98 (m, 1H); 2.35-2.21 (m 2H); 2.17 (s, 6H); 1.88-1.78 (m, 2H).
Example 7 [0200] Hard gelatin capsules containing the following ingrédients are prepared:
Quant ity
Ingrédient
Active Ingrédient
Starch (mg/capsule)
30.0
305,0
Magnésium stéarate 5.0
The above ingrédients are mixed and filled into hard gelatin capsules.
Example 8 [0201] A tablet of a compound of Formula (I) is prepared using the ingrédients below:
Quantity
Ingrédient | (mg/tablet) |
Active Ingrédient | 25.0 |
Cellulose, microcrystalline | 200.0 |
Colloïdal silicon dioxide | 10.0 |
Stearic acid
5.0
The components are blended and compressed to form tablets.
Example 9 [0202] A dry powder inhaler formulation is prepared containing the following components:
Ingrédient
Active Ingrédient
Lactose
Weight % |0203] The active ingrédient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.
Example 10 [0204] Tablets, each containing 30 mg of active ingrédient, are prepared as follows:
Quantity | |
Ingrédient | (mg/tablet) |
Active Ingrédient | 30.0 mg |
Starch | 45.0 mg |
Microcrystalline cellulose | 35.0 mg |
Polyvinylpyrrolidone | |
(as 10% solution in stérile water) | 4.0 mg |
Sodium carboxymethyl starch | 4.5 mg |
Magnésium stéarate | 0.5 mg |
Talc | 1.0 mg |
Total | 120 mg |
[0205] The active ingrédient, starch, and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the résultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50 °C to 60 °C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnésium stéarate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mîxing, are compressed on a tablet machine to yield tablets each weighing 120 mg.
Examplc 11 [0206] Suppositoires, each containing 25 mg of active ingrédient, are made as follows:
Ingrédient
Active Ingrédient
Saturated fatty acid glycerides to
Amount mg
2,000 mg [0207] The active ingrédient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.
Example 12 [0208] Suspensions, each containing 50 mg of active ingrédient per 5.0 mL dose, are made as follows:
Ingrédient | Amount |
Active Ingrédient | 50.0 mg |
Xanthan gum | 4.0 mg |
Sodium carboxymethyl cellulose (11%) | |
Microcrystalline cellulose (89%) | 50.0 mg |
Sucrose | 1.75 g |
Sodium benzoate | 10.0 mg |
Flavor and Color | q.v. |
Purified water to | 5.0 mL |
[0209] The active ingrédient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufïicient water is then added to produce the required volume.
Example 13 [0210] A subcutoneous formulation may be prepared as follows:
Ingrédient
Active Ingrédient
Corn Oil
Quanti ty
5.0 mg
1.0 mL
Example 14 [0211] An injectable préparation is prepared having the following composition:
Ingrédients
Active ingrédient
Mannîtol, USP
Gluconic acid, USP
Amount
2.0 mg/mL mg/mL
q.s. (pH 5-6) water (distîlled, stérile)
Nitrogen Gas, N F
q.s. to l .0 mL
q.s.
Example 15 [0212] A topical préparation is prepared having the following composition:
Ingrédients grams
Active ingrédient 0.01-1
Span 602.0
Tween 602.0
Minerai oil5.0
Petrolatum0.10
Methyl paraben0.15
Propyl paraben0.05
BHA (butylated hydroxy anisole)0,01
Water q.s. to 100 [0213] Ail of the above ingrédients, except water, are combined and heated to 60 °C with stirring. A sufficient quantity of water at 60 °C is then added with vigorous stirring to emulsify the ingrédients, and water then added q.s. 100 g.
Example 16
Sustained Release Composition
Weight
Ingrédient Range (%) Range 1 (%) Range 2 (%)
Active ingrédient | 50-95 | 70-90 | 75 |
Microcrystalline cellulose (filler) | 1-35 | 5-15 1 | 0.6 |
Methacrylic acid copolymer | 1-35 | 5-12.5 | 10.0 |
Sodium hydroxide | 0.1-1.0 | 0.2-0.6 | 0.4 |
Hydroxypropyl methyl cellulose | 0.5-5.0 | 1-3 | 2.0 |
Magnésium stéarate | 0.5-5.0 | 1-3 | 2.0 |
[0214] The sustained release formulations are prepared as follows: compound and pH-dependent binder and any optional excipients are intimately mixed (dry-blended). The dry-blended mixture is then granulated in the presence of an aqueous solution of a strong base which is sprayed into the blended powder. The granulate is dried, screened, mixed with optional lubricants (such as talc or magnésium stéarate), and compressed into tablets. Certain aqueous solutions of strong bases are solutions of alkali métal hydroxides, such as sodium or potassium hydroxide, preferably sodium hydroxide, in water (optionally containing up to 25% of water-miscible solvents such as lower alcohols).
[0215] The resultîng tablets may be coated with an optional film-forming agent, for identification, taste-masking purposes and to improve ease of swallowing. The film forming agent will typically be présent in an amount ranging from between 2% and 4% of the tablet weight. Suitable film-forming agents are well known to the art and include hydroxypropyl, methylcellulose, cationic méthacrylate copolymers (dimethylami no ethyl méthacrylate/ methyl-butyl méthacrylate copolymers - Eudragit® E - Rôhm. Pharma) and the like. These film-forming agents may optionally contain colorants, plasticizers, and other supplémentai ingrédients.
|0216] The compressed tablets preferably hâve a hardness sufficient to withstand 8 Kp compression. The tablet size will dépend primarily upon the amount of compound in the tablet. The tablets will include from 300 to 1100 mg of compound free base. Preferably, the tablets will include amounts of compound free base ranging from about 10-200 mg, 100-300 mg, or 400-600 mg.
|0217] In order to influence the dissolution rate, the time during which the compound containing powder is wet mixed is controlled. Preferably the total powder mix time, i.e., the time during which the powder is exposed to sodium hydroxide solution, will range from 1 to 10 minutes and preferably from 2 to 5 minutes. Following granulation, the particles are removed from the granulator and placed in a fluid bed dryer for drying at about 60°C.
Examplc 17 [0218] ALDH2 Assays
Standard ALDH2 reaction mixtures contained 150 uM formaldéhyde, 2.5 mM NAD+, 10 mM MgC12 and 10 nM recombinant human ALDH2 in 50 mM Hepes buffer, pH 7.4, 0.01%Tween 20 in a final volume of 50 ul using 384-well plates. After 60 min of preincubation of compound with ALDH2 and formaldéhyde, the reaction was started by adding
NAD+ and the reaction mixture was allowed to proceed for 90 minutes. Activity of the enzyme was determined by monitoring NADH formation using Perkin-Elmer Envision Reader with excitation and émission wavelengths set at 340 and 460 nm, respectively.
MAO-A and MAO-B Assays
MAO assays included luminogenic MAO substrate, reaction bufters, Luciferin Détection and the reconstitution buffer with esterase. Standard MAO reaction mixtures included microsome contained MAO-A (2 ug) or MAO-B (10 ug), l60uM substrate for MAO-A or l6uM substrate for MAO-B, MAO-A buffer (100 mM Hepes buffer, pH 7.5, 5% glycerol) or MAOB buffer (100 mM Hepes, pH 7.5, 5% glycerol, 10% dimethyl sulfoxide) in a final volume of 30 ul. After 20 minutes of pre-incubation of the enzyme with compounds, the reaction was initiated by adding enzyme substrate and the reaction was allowed to proceed for 60 minutes. Reconstituted Luciferin Détection Reagent (30 ul) was then added is added to simultaneously stop the MAO reaction and convert the methyl ester dérivative to luciferin and produce light. The amount of light produced is directly proportional to the activity of MAO. The mixtures were further incubated for 20 minutes and activity of the enzyme was determined using Perkin-Elmer Envision Reader.
Note: IC50 refers to the concentration of a compound that inhibits a reaction by 50%. ln the case of compétitive inhibition, IC50 = 2Ki when the substrate is présent at the Km concentration, as per the relationship: Ki = IC50/[ 1 + (substrate concentration/Km)].
[0219] Représentative data for several compounds are presented in Table 1 below.
TABLE 1 - ALDH-2 AND MAO INHIBITION | ||||
NUMBER | COMPOUND | icso HALDI12 NM | ICÎO HMAO-A μΜ | ICM HMAO-B μΜ |
1 | 2,6-dichloro-4-(2-methoxyethoxy)-7V-(4-(2-oxo -1,2-dihydropyridin-4-yl)benzyl)benzamide | 63 | >130 | >130 |
2 | 2,6-dichloro-JV-[4-(2-oxo-1,2-dihydrO'pyridin -4-yl)-benzyl]-benzamide | 102 | >130 | >130 |
TABLE 1 - ALDH-2 AND MAO INHIBITION | ||||
NUMBER | COMPOUND | ICS0 HALDII2 NM | IC5O HMAO-A pM | IC50 I1MAO-B pM |
3 | 2-chloro-3-fluoro-Ar-(4-(2-oxo-l,2-di hydropyridin-4-yl)benzyl)benzamide | 215 | >130 | >130 |
4 | 2-chloro-6-melhyl-jV-(4-(2-oxo-1,2-di hydropyridin-4-yl)benzyl)benzamide | 23 | >130 | >130 |
5 | 2,6-dimethyl-AÎ-(4-(2-oxo-l,2-dihydropyridin-4 -yl)benzyl)benzamide | 166 | >130 | >130 |
6 | 2,6-dichloro-Af-[4-(6-methyl-2-oxo-l,2-diliydro -pyridin-4-yl) -benzy 1] -benzamide | 1113 | >130 | >130 |
7 | 2-chloro-3,6-difluoro-7V-(4-(2-oxo-l,2-di hydropyridin-4-yl)benzyl)benzatuide | 464 | >130 | >130 |
8 | 2,6-dichloro-/V-(3-niethyl-4-(2-oxo-l,2-di hydropyridin-4-yl)benzyl)benzaniide | 480 | >130 | >130 |
9 | 2,6-dichloro-jV-(4-( l-methyl-2-oxo-l,2-di hydropyridin-4-yl)benzyl)benzaniide | 2093 | >130 | >130 |
10 | 2,6-difluoro-Y-(4-(2-oxo-l,2-dihydropyridin-4 -yl)benzyl)benzamide | 890 | >130 | >130 |
11 | 2-chloro-â-fluoro-Y-(4-(2-oxo-l ,2-di hydropyridin-4-yl)benzyl)benzamide | 379 | >130 | >130 |
12 | 2,6-diciiloro-jV-(2 - fl uoro-4-(2-oxo-1,2-di hydropyridin-4-yl)benzyl)benzamÎde | 304 | >130 | >130 |
13 | 2,6-dichloro-Af-(4-(5-fluoro-2-cxo-l,2-di hydropyridin-4-yl)benzyl)benzaniide | 25 | >130 | >130 |
14 | phosphoric acid mono-(4-{4-[(2,6dîchloro-benzoylamino)-methyl]-phenyl}-2 -oxo-2H-pyridin-1 -ylmethyl) ester | >10000.00 | >129.51 | >130 |
The above data suggests that compounds of the invention generally inhibit the ALDH2 enzyme with an IC50 of less than l uM.
Example 18
Réduction of Alcohol Dependency [0220] Animais: The strains of alcohol-preferring rats are housed individually in stainlesssteel wire mesh cages (26'34 '20 cm) under constant température of 21 ± 1°C and reversed 12 hour light-12 hour dark cycle (10:00-22:00 dark). These rats consume significantly more alcohol than their respective control strains: the selectively-bred alcohol non-preferring (NP), the low alcohol-drinking (LAD) rat, and the Wistar rat. The FH and P rats are derived from the Wistar rat. Water and food (Agway Prolab Rat/Mouse/Hamster 3000 formula, Agway, Syracuse, USA) are provided ad lib.
[0221] Establishment of Baseline: Following the standard method (Murphy et al., 1988; Rezvani and Grady, 1994; Rezvani et al., 1995), alcohol-preferring rats are given 1 day access to water in a Richter tube followed by 3 days of free access to a solution of 10% (v/v) éthanol given as the only source of fluid. Thereafter, the rats are given a choîce between alcohol and water for the remainder of the study. Ail experiments involve 24 hour free access to food, water, and alcohol in a two-bottle choice paradigm.
[0222] Experimental Protocol: After establishment of a stable baseline for alcohol and water intakes, animais are maintained on a continuous access to alcohol and water via a twobottle choice paradigm for about 2 months. Then, rats receive a single i.p. injection of the saline vehicle, or a test compound at 09:30 am. Alcohol and water intakes are measured at 6 and 24 hours after the injection. Food intake is measured 24 hours after the injection.
[0223] Chronic Systemic Administration: A chronic experiment is conducted with adult male P rats. After establishment of stable baselines for alcohol and water intakes, and following a cross-over design, the test drug or vehicle is given i.p. once a day for 10 consecutive days. Alcohol and water intakes are measured at 6 and 24 hours after the treatment, whereas food intake is measured 24 hours after the treatment. Each rat receives both treatments, and a washout period of 3 days is imposed between treatments.
[0224] Statistical Analysis: The results are expressed as means ± standard error of means (SEM). Alcohol intake (g/kg) is calculated by multiplying the volume of alcohol consumed by 10% and 0.7893 (éthanol density)/animal body weight in kg. Alcohol preference, expressed as a percentage, is calculated as follows: (volume of alcohol consumed in mL/total fluid intake in mL) x 100 (Rezvani et al., 1990; Rezvani and Grady, 1994). Statistical différences between different groups are determined using analysis of variance followed by Newman-Keuls protected t-test.
Rat alcohol self administration
Alcohol-preferring (iP) male rats were trained to daily (Monday to Friday) self-administer alcohol (10% v/v) under opérant conditions. A fixed-ratio of 3 (FR3), where rats had to press a lever 3 fîmes to get one drop of alcohol during 20-min sessions was used (Cowen et al, 2005a; Cowen et al., 2005b; Lawrence et al., 2006). Availability of alcohol was conditioned by the presence of an olfactory eue (2 drops of vanilla essence, placed on the bedding of the opérant chamber directly under the active lever), plus a 1-sec light stimulus when FR3 was obtained. For each session, total alcohol and water responses were recorded. Following acquisition of lever pressing behavior and stable alcohol self-administration, rats were administered oral vehicle or compound of Example 5 (5, 10 and 30 mg-eq/kg) 1 hr before each session in a counterbalanced order. Every rat received ail drug doses and vehicle once per week in a randomly assigned order. Compound of Example 5 at 10 and 30 mg-eq/kg significantly decreased the number of lever presses for alcohol (Figure 1).
Example 19
Réduction of Cocaïne Dependency and Relapse [0225] Intravenous cocaïne (0.35mg/kg/inj) is used in an opérant self administration and reinstatement mode! in rats. In this model, rats addicted to cocaïne repeatedly press a lever to obtain an intravenous dose (iv) of cocaïne. When cocaïne is removed, rats stop pressing the lever. However, rats résumé lever pressing for cocaïne (reinstatement) if subjected to a small intraperitoneal (ip) dose (lOmg/kg) of cocaïne that normally has no effect in naïve animais. This îs a valid animal model of relapse in cocaïne addicted humans, and tests the ability of the compounds of Formula (I) to block cocaïne craving and relapse.
[0226] Male Sprague-Dawley rats with jugular vein catheterization are used. Rats are presented with a choice of two levers in the test/training chamber. Dépréssion of the active lever results in delivery of a cocaïne reinforcer, while dépréssion of the inactive lever does not resuit in reinforcement. During the initial 15 hour fixed ratio (FR) 1 training session (FRI stands for one lever press equals one reinforcement delivery), a food pellet is taped to the active lever to facilitate lever pressing, and each active lever press results in the delivery of a single 45 mg food pellet (Noyés, Lancaster, NH). The following day the reinforcer is switched to FRI lever pressing for cocaïne (0.35 mg/kg/inj, delivered in 0.27 sec). Cocaïne reinforcement is delivered on a modified FRI schedule such that each drug infusion is accompanied by illumination of a stimulus over the active lever and a 20 second timeout during which active lever presses are counted but do not resuit in reinforcer delivery. After 20 seconds the stimulus light is tumed off and the first lever press again results in drug delivery. Dépréssion of the inactive lever does not hâve any conséquence. Daily training sessions for each group lasts 2 hours, or until a subject eams 200 drug infusions, whichever cornes first. The subjects romain in drug self-administration training mode until acquisition criterion is met (average presses on the active lever varied by < 10% over 3 consecutive training days). This typically takes 10-14 days.
Extinction and Reinstatement [0227] For extinction and reinstatement experiments, rats are required to display stable responding (variability not higher than 15% in 2 consecutive sessions) on the FRI schedule of reinforcement. After achieving these criteria, extinction procedures begin such that lever presses no longer resuit in delivery of the reinforcer. When average responding across three consecutive extinction sessions falls to 15% of responding during maintenance, subjects are tested for reinstatement. In ***e-experienced animais, reinstatement is primed with a noncontingent injection of cocaïne (10 mg/kg ip) immediately before the reinstatement session. In order to increase statistical power and therefore decrease animal usage, a second extinction period is initiated 3-4 days after the first, which allows for additional within-subjects comparisons. Experiments use a between-session-training and testing method in which animais are trained to self administer drug. Their behavior is then extinguished and then reinstatement is primed on different days.
Results: Effect of Compounds of Formula (I) on cocaïne induced relapse [0228] Ip injections of the compounds of Formula (I) dose dependently block relapse for cocaïne. Animais are trained to self administer cocaïne (0.35 mg/kg/inj) until they reach stable responding. They are then trained in the same chambers but cocaïne is no longer available. Once they drop their lever presses responding to a minimal level (extinction), they are then given a primîng dose of cocaïne (10 mg/kg) and consequently their responding lever presses significantly increase (relapse). Those same animais receiving effective compounds of Formula (I) prior to the priming injection of cocaïne do not show an increase in their lever presses responding (did not relapse).
Rat Cocaïne Cue Reinstatement
Training of male Sprague Dawley (SD) rats had 3 separate stages. First, during self administration, animais were trained to lever press for cocaïne with présentation of concomitant eues associated with drug delivery. Rats that reached criteria for addiction were included in the study. Afterward, during cue extinction, ***e-cue dépendent behavior was extinguished. Lastly, during cocaïne cue reinstatement, the effect of compounds was tested on lever presses upon cue présentation (Fig. 2).
Cocaïne self administration
Rats were trained to self administer i.v. cocaïne (0.35 mg/kg/injection) daily (Monday to Friday) în standard opérant chambers with rétractable levers (Coulboum Instruments, PA). During the daily 2 hr session, rats received a 0.05 ml infusion of 0.35 mg/kg cocaïne every time the active lever was pressed. A cue light and tone tumed on for 2 sec together with activation of a pump that delïvered the cocaïne solution. Rats were required to maintain an infusion rate of > 20+ per day for at least 10 days before being moved to extinction training. Rats that did not reach this criterion were excluded from the study.
Cue extinction
During extinction sessions lever presses no longer produced cocaïne infusion and cue light/tone présentation was absent. Rats received a maximum of 15 extinction sessions. Rats were considered to hâve extinguished behavior when during 2 consecutive sessions they exhibited an average of < 15 active lever presses or 30% of the number of responses per session that occurred during the last 2 sessions of cocaïne self-administration, whichever came first.
Cocaïne cue reinstatement
On the next day after reaching extinction criteria, rats were treated orally with vehicle (Formulation 2B: 25% PEG400/5% Vit E TPGS/l% SLS/69% water with 0.5% Methocel) or drug (compound of Example 2 or compound of Example 5) before the cue reinstatement session. Cue reinstatement began with a tone and cue light. This 2 hr session was identical to the self-admïnistration session (cue light and tone présent upon active lever press) except that no cocaïne was delivered. The number of active lever presses was compared to extinction lever responding. This is considered a measure of reinstatement. The next day, rats were retumed to extinction sessions for at least 2 or 3 more sessions. Rats then received a second and last reinstatement session with an opposite treatment to the one received on the first reinstatement session (vehicle or dru g treatment). When rats pretreated with vehicle are presented with eues associated with cocaïne availability, they significantly increase their number of lever presses. The light/tone présentation triggers this response and it is interpreted as a measure of reinstatement even though cocaïne is not available.
Compound of Example 2 significantly reduced cocaïne cue-induced reinstatement in SD rats by 69%, 72% and 86% at 5, 10 and 30 mg/kg, respectively, when compared to vehicle (Figure 3). An ANOVA revealed a significant effect of treatment on number of lever presses. A significant effect of treatment was observed for ail doses tested (p<0.001). Fisher post-hoc comparisons showed that rats treated with vehicle prior to eue reinstatement session had a significant increase in number of lever presses when compared with extinction session (p< 0.05). After treatment with compound of Example 2 (5, 10 or 30 mg/kg) prior to eue reinstatement session, rats significantly decreased lever presses responding compared with vehicle treatment (69% inhibition: p<0.05, 72% inhibition: p<0.05 and 86% inhibition: p<0.0l, respectively). #p < 0.01 compared with extinction; * p<0.05 and ** p < 0.01 compared with vehicle.
The prodrug compound of Example 5 was efficacious at 5,10 and 30 mg-eq/kg in cocaïne eue reinstatement with 59%, 55% and 50% inhibition, respectively (Figure 4). At the lowest dose tested, 2.5 mg-eq/kg, the effect was not significantly different from vehicle.
Compound of Example 5 reduced cocaïne cue-induced reinstatement in SD rats. The number of lever presses was recorded during the 2 hr cue-induced reinstatement session. An ANOVA revealed a significant effect of treatment on number of lever presses. Rats that had extinguished lever press responding were treated with oral vehicle and compound of Example 5 (2.5,5, 10 or 30 mg-eq/kg) 1 hr before the cue-induced reinstatement session. A significant effect of treatment was observed for 2.5, 5, 10 and 30 mg-eq/kg doses tested (2.5 mg/kg eq: F(2,28)= 9.39, p<0.01, n=15', 5 mg/kg eq: F(2,14)=11,47, p<0.01, n =8‘, 10 mg/kg eq: F(2, 18)=13,901, p<0.001, n =10\ 30 mg/kg eq: F(2, 22)=18.221, ρθ.001, n =12). Fisher posthoc comparisons revealed that rats treated with vehicle prior to eue reinstatement session showed a significant increase in number of lever presses when compared with extinction session (p< 0.01). After treatment with compound of Example 5 (5,10 or 30 mg/kg) prior to eue reînstatement session, rats significantly decreased lever presses responding compared with vehicle treatment (59% inhibition: p<0.05,55% inhibition: p<0.01 and 50% inhibition: p<0.01, respectively). Fisher post-hoc comparisons revealed that 2.5 mg/kg eq dose was not significantly different from vehicle (30% inhibition, p>0.05, N.S.). #p < 0.01 compared with extinction; * p<0.05 and ** p< 0.01 compared with vehicle).
Examplc 20
Réduction of Nicotine Dependency [0229] Biological Material: Wistar-derived male rats (250-300 g) are housed in groups of two and maintained in a temperature-controlled environment on a 12 hour:12 hour light cycle (0600h on-1800h off), upon arrivai in the laboratory. Animais are given free access to food and water during a one-week habituation period to the laboratory. Animais used in the research studies are handled, housed, and sacrificed in accord with the current NIH guidelines regarding the use and care of laboratory animais, and ail applicable local, state, and fédérai régulations and guidelines. Animais are handled daily for several days to desensitize them to handling stress before experimental testing. Sample sizes (e.g., n=8) are sufficient to provide reliable estimâtes of drug effects.
[0230] Drug Treatments: The Wistar-derived rats receive several doses of the compounds of Formula (I) administered intraperitonealy (i.p.), and a positive control compound, mecamylamine (1.5 mg/kg, subcutaneously (s.c.). The compounds are administered 30 minutes prior to SA sessions. The compounds of Formula (I) are administered at 2 mL/kg for the 7.5 mg/kg (3.75 mg/mL) and 10 mg/kg (5 mg/mL), doses, and at 3 mL/kg for the 15 mg/kg dose (5 mg/mL). The compound is dissolved in corn oil (VEH), and sonicated for at least 30-minutes, up to 2 hours prior to administration. Mecamylamine is dissolved in 0.09% isotonie saline and administered at a volume of 1 mL/kg.
[0231] Apparatus: Food training and nicotine self-administration takes place in 8 standard Coulboum opérant chambers. Each chamber is housed in a sound-attenuated box. Opérant chambers are equipped with two levers; mounted 2 cm above the floor, and a eue light mounted 2 cm above the right lever on the back wall of the chamber. For food training, a food hopper is located 2-cm to the left/right of either lever, in the middle of the back wall.
Intravenous infusions are delivered in a volume of 0.1 mL over a 1 second interval via an infusion pump (Razel, CT) housed outside of the sound attenuated chamber.
[0232] Food Training: Lever pressing is established as demonstrated by the method of Hyytia et al., (1996). Initially, rats are restricted to 15 grams of food daily (approximately 85% of their free-feeding body weight). After the second day of food restriction, rats are trained to respond for food under a fixed-ratio 1 (FRI) schedule of reinforcement (1 food pellet for each lever press) with a 1 second time-out (TO-ls) after each reinforcement. Training sessions are given twice per day, and TO periods are gradually increased to 20 seconds. Once rats obtain a steady baseline responding at a FRl-TO20s schedule of reinforcement, they are retumed to ad libitum food prior to préparation for intravenous jugular cathéter implant surgery.
[0233] Surgery: Rats are anesthetized with a ketamine/xylazine mixture and chronic silastic jugular cathéters are inserted into the extemal jugular vein and passed subcutaneously to a polyethylene assembly mounted on the animal’s back. The cathéter assembly consists ofa 13-cm length of silasitic tubing (inside diameter 0.31 mm; outside diameter 0.64 mm), attached to a guide cannula that is bent at a right angle. The cannula is embedded into a dental cernent base and anchored with a 2 x 2 cm square of durable mesh. The cathéter is passed subcutaneously from the rats back to the jugular vein where it is inserted and secured with a non-absorbable silk suture. Upon successful completion of surgery, rats are given 3-5 days to recover before self -administration sessions are started. During the recovery period, rats remain ad libitum food access, and hâve cathéter lines flushed daily with 30 units/mL of heparinized saline containing 66 mg/mL of Timentin to prevent blood coagulation and infection in the cathéters.
[0234] Nicotine Self-Administration: Following successful recovery from cathéter implant surgery, rats are again food deprived to 85% of their free-feeding body weight. Once selfadministration sessions begin, subjects are trained to IV self-administer nicotine in 1-hour baseline sessions, 5 days per week, under a FRI -TO-20 schedule of reinforcement until stable responding is achieved. Stable responding is defined as less than 20% variability across 3 consecutive sessions. After acquisition of stable responding for nicotine, various doses of the compounds of Formula (I) are tested using a within-subjects Latin square design. Rats are allowed to self -administer nicotine after treatment with each dose of the compounds of Formula (I) for 1 test session, and subsequently “rebaselined” for 1-3 days before the next dose probe during one test self-administrations sessions, Following the testing of the first compound, rats receive the positive control compound, mecamylamine (1.5 mg/kg), adminîstered according to a crossover design.
[0235] During SA sessions, rats are flushed with saline before test session to ensure cathéter patency, and again flushed after test sessions with 30 units/mL of heparinized saline containing 66 mg/mL of Timentin, to prevent blood coagulation and infection in the cathéters. If cathéter patency is in question, as demonstrated by an unexpected shift in response rates, or inability to draw blood from the cathéter, 0.1 mL of a short-acting anesthetic (Brevital) is infused. Animais with patent cathéters exhibit rapid loss of muscle tone within 3-seconds. Rats with cathéters no longer patent according to the Brevital test are removed from the experiment.
[0236] Data Analysis: Data is collected on-line from multiple opérant chambers, and reported as mean cumulative number of bar presses for nicotine. The data is analyzed using the StatView statistical package on a PC-compatible computer.
Results: The Effect of Compounds on Nicotine Self Administration:
[0237J Increasing doses of the compounds of Formula (I) administered as described in the above protocol reduce the number of bar presses (plotted as the number of infusions) for nicotine administration.
Rat nicotine self administration
Acute treatment
Male SD rats were trained to self administer i.v. nicotine (0.03 mg/kg/inj) daily (Monday to Friday) in standard opérant chambers with rétractable levers (MED Associâtes, Inc) as previously published (Levin et al., 2003; Levin et al., 2007). During the daily 45 min session, rats received 0.05 ml infusion of 0.03 mg/kg/infusion of nicotine every tïme the active lever was pressed. A eue light and tone tumed on for 0.5 sec together with the activation of a pump that delivered the nicotine solution. Daily sessions were run for at least 10 days before the initiation of drug testing. Solutions of compounds of Example 2 and Example 5 were prepared fresh daily in Formulation 2B: 25% PEG400/5% Vit E TPGS/l% SLS/69% water with 0.5% Methocel) for oral dosing. Compound of Example 2 doses were administered in a counterbalanced design for testing l hr before each nicotine session. Every rat received ail drug doses and vehicle in a randomly assigned order. The oral drug administrations were made twice per week. Compound of Example 2 at 10, 30 and 60 mg/kg significantly reduced the number of nicotine infusions when compared to vehicle treatment (26%, 28% and 31 % inhibition, respectively). Doses of l and 5 mg/kg were without effect (Figure 5).
Compound of Example 5 was tested in a study using 4 independent groups. Each group received eîther oral vehicle or 1 of the 3 doses of compound of Example 5 (5, 10 or 30 mgeq/kg). The 2 higher doses of compound of Example 5 (10 and 30 mg-eq/kg) significantly reduced the number of nicotine infusions when compared to vehicle treatment (51% and 68% inhibition, respectively). The 5 mg/kg dose was ineffective.
Chronic treatment
Upon completion of the acute compound of Example 5 treatment study, the same animais were used to test tlie effect of 7-day chronic oral administration of compound of Example 5 in the nicotine self administration model. Rats were treated oraily with compound of Example 5 (5,10 or 30 mg-eq/kg) or vehicle 1 hr before nicotine self administration session for 7 consecutive days. Compound of Example 5 at 10 and 30 mg-eq/kg significantly reduced the number of nicotine infusions when compared to vehicle treatment during the Ί days of chronic oral administration (48% and 62% inhibition, respectively). Similar to the acute treatment, the 5 mg-eq/kg dose was ineffective (Figure 7). There was no development of tolérance to the therapeutic effect during the course of the study (data not shown). Animais in nicotine self administration studies had to reach pre defined criteria (e.g. rat strain, minimum number of nicotine infusions, consistent baseline nicotine self administration throughout the study, patent iv cathéters, etc.) to be included in analysis.
Claims (15)
1. A compound of Formula (la):
wherein:
R1 is hydrogen, optionally substituted C,.6 alkyl, -CH2OH, -CH2OP(O)(OR20)(OR21), -C(O)R22, or-SO2R23;
R2 is hydrogen, optionally substituted C|.e alkyl, cycloalkyl, or halo;
each of R3, R4, R5, R6, R9, R10, R11, R12 and R13 is independently hydrogen, hydroxyl, -OP(O)(OR20)(OR21), -CH2OH, -CH2OP(O)(OR20)(OR21), optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, aminocarbonyl, acyl, acylamino, -O-(Ct to Cû-alkyl)O-(C] to Ce-alkyl), cyano, halo, -SO2NR24R25; or -NR24R25;
R is hydrogen or optionally substituted Cj^ alkyl;
each of R20 and R21 is independently Na+, Li+, K+, hydrogen, Ci-β alkyl; or R20 and R can be combined to represent a single divalent cation Zn , Ca , or Mg .
each of R22 and R23 is independently optionally substituted alkyl, optionally substituted alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, or -NR24R25; and each of R24 and R25 is independently chosen from hydrogen or C(_6 alkyl or when combined together with the nitrogen to which they are attached form a heterocycle; or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
2.6- dimethyl-N-(4-(2-oxopiperidin-4-yl)benzyl)benzamide; or a pharmaceutically acceptable sait, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
25. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of daims 2-24 and a pharmaceutically acceptable carrier.
27. The use of claim 26, wherein the dopamine-producing agent is selected from the group consisting of cocaïne, opiates, amphétamines, nicotine, and alcohol.
5
28. Use of a compound according to any one of claims 2-24 or a pharmaceutîcal acceptable sait, or prodrug thereof in the manufacture of a substance for decreasing alcohol consumption in a mammal.
29. Use of a compound according to any one of claims 2-24 or a pharmaceutically
2.6- dichloro-7V-(4-(5-ftuoro-2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide; and phosphoric acid mono-(4-{4-[(2,6-dichloro-benzoylamino)-methyl]-phenyl}-2-oxo-2H -pyridin-l-ylmethyl) ester;
2.6- dichloro-7V-(2-fluoro-4-(2-oxo-1,2-dîhydropyrid i n-4-yl)benzyl)b enzami de;
2-chloro-6-fluoro-7V-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide;
2.6- difluoro-7V-(4-(2-oxo-l,2-dihydropyridin-4-yI)benzyl)benzamide;
2.6- dichloro-JV-(4-( 1 -methyl-2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
2.6- dichloro-7V-(3-methyl-4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide);
2-chloro-3,6 -difl uoro-A-(4-(2-oxo-1,2-dihydrop yri d i n-4-yl)benzyl)benzamide;
2.6- dichloro-7V-[4-(6-methyl-2-oxo-1,2-di hydro -pyridi n-4-yl) -benzyl] -benzamide;
2.6- dimethyl-A'-(4-(2-oxo-1,2-dihydropyridin-4-yl)benzyl)benzamide;
2-chloro-6-methyl-7V-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide;
2-chloro-3-fluoro-A-(4-(2-oxo-l,2-dihydropyridin-4-yl)benzyl)benzamide;
2.6- dichloro-7V-[4-(2-oxo-l,2-dihydro-pyridin-4-yl)-benzyl]-benzamide;
2.6- dichloro-4-(2-methoxyethoxy)W-(4-(2-oxo-l,2-dihydropyridin-4-yl) benzyl)benzamide;
2. A compound of formula (I) wherein:
R1 is hydrogen, optionally substituted Cj.6 alkyl, -CH2OH, -CH2OP(O)(OR20)(OR21);
R is hydrogen, optionally substituted C|.6 alkyl, cycioalkyl, or halo;
each of R3, R4, R5, R6, R9, R10, R11, R12 and R13 is independently hydrogen, hydroxyl, -OP(O)(OR20)(OR21), -CH2OH, -CH2OP(O)(OR20)(OR21), optionally substituted alkyl, optionally substituted alkylene, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted cycioalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, optionally substituted heteroaralkyl, optionally substituted heterocyclyl, aminocarbonyl, acyl, acylamino, -O-(Cj to Câ-alkyl)O-(Ci to Ce-alkyl), cyano, halo, -SO2NR24R25; or -NR24R2S;
R7 is hydrogen or optionally substituted Ci.& alkyl;
20 21 4 f i 20 each of R and R is independently Na , Li , K , hydrogen, C|.g alkyl; or R and R21 can be combined to represent a single divalent cation Zn2+, Ca2+, or Mg2+. each of R22 and R23 is independently optionaily substituted alkyl, optionaily substituted alkoxy, optionaily substituted cycloalkyl, optionaily substituted aryl, or-NR24R25; and each of R24 and R25 is independently chosen from hydrogen or Ci.6 alkyl or when combined together with the nîtrogen to which they are attached form a heterocycle; or a pharmaceutically acceptable sait, ester, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
3. A compound of formula (Ib) wherein:
R1 is hydrogen, C,.6 alkyl, -CH2OR22, -CH2OP(O)(OR20)(OR21);
«
R is hydrogen, cyano, Cm alkyl, C3-C6 cycloalkyl, or halo;
each of R3, R4, Rs, R6, R9, R10, R1 ’, R12 and R13 is independently hydrogen, halo, Cr Cg alky, hydroxyl, or -CH2OR22;
π
R is hydrogen or Cm alkyl;
each of R20 and R21 is independently Na+, Li+, K+, hydrogen, or Cm alkyl;
each R22 is independently hydrogen, Ci-Ce alkyl, C3-C6 cycloalkyl, phenyl or benzyl;
or a pharmaceutically acceptable sait, single stereoisomer, mixture of stereoisomers, or tautomer thereof.
4. The compound of claim 2, wherein R1 is hydrogen.
5. The compound of claim 2, wherein R1 is Cm alkyl.
6. The compound of claim 2, wherein R1 is methyl.
7. The compound of claim 2, wherein R1 is -CH2OP(O)(OR20)(OR21); and each of R20 and R21 is independently Na+, Li+, K+, or hydrogen.
8. The compound of any one of daims 2, wherein R is hydrogen, C].e alkyl, or halo.
9. The compound of any one of daims 2, wherein R is methyl, fluoro or chloro.
10 acceptable sait or prodrug thereof in the manufacture of a médicament for treating obesity in a mammal
30. A compound according to any one of claims 2-24 for use in therapy.
10. The compound of any one of daims 2, wherein each of R3, R4, Rs, and R6 is independently hydrogen, Ci-6 alkyl, or halo.
11. The compound of any one of daims 2, wherein one of R3, R4, R5, or R6 is methyl or fluoro.
12. The compound of any one of daims 2, wherein R7 is hydrogen or methyl.
13. The compound of any one of daims 2, wherein at least one of R9 and R13 is not hydrogen.
14. The compound of any one of daims 2, wherein at least one of R9 and R13 is halo or C i-6 alkyl.
15. The compound of any one of daims 2, wherein each of R9 and R13 is independently chloro or methyl.
16. The compound of any one of daims 2, wherein each of R10 and R12 is independently hydrogen, chloro, fluoro, or methyl.
17. The compound of any one of daims 2, wherein Rl0, R11 and R12 are each hydrogen.
18. The compound of any one of daims 2, wherein R11 is -O-(C| to Ce-alkyl)-O-(Ci to C6-alkyI).
19. The compound of any one of daims 2, wherein R11 îs -OCH2CH2OCH3.
20. The compound of claim 2, wherein:
R1 is hydrogen, methyl, or -CH2OP(O)(OR20)(OR21);
R2 is hydrogen, methyl, or fluoro;
each of R3 or R4 is independently hydrogen or methyl;
each of R5 and R6 is independently hydrogen or fluoro;
R7 is hydrogen;
R9 is hydrogen, chloro, fluoro, or methyl;
R10 is hydrogen or fluoro;
R is hydrogen or -OCH2CH2OCH3;
R is hydrogen or fluoro;
R13 is hydrogen, chloro, fluoro, or methyl; and each of R20 and R21 is independently Na+, Li+, K+, or hydrogen.
21. The compound of claim 2, wherein the structure is:
Cl
NH or a pharmaceutically acceptable sait, or tautomer thereof.
The compound of claim 2, wherein the structure is:
Cl O
O
22.
23. The compound of claîm 2, wherein the structure is:
or a pharmaceutically acceptable sait, ester, or tautomer thereof.
24. A compound selected from the group consisting of:
15 31. Use of a compound according to any one of claims 2-24 for the manufacture of a médicament for the treatment of diseases related to addiction to dopamine producing agents.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61/503,923 | 2011-07-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16801A true OA16801A (en) | 2016-01-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10507215B2 (en) | Compounds for the treatment of addiction | |
US7951813B2 (en) | Quinazolinone derivatives as ALDH-2 inhibitors | |
JP2008501700A (en) | Factor VIIa inhibitor | |
OA16801A (en) | Compounds for the treatment of addiction. | |
AU2016244324A1 (en) | Compounds for the treatment of addiction | |
AU2015202264A1 (en) | Compounds for the treatment of addiction | |
NZ618537B2 (en) | Mitochondrial aldehyde dehydrogenase (ALDH-2) inhibitors | |
US20210145844A1 (en) | Combination therapy for nicotine addiction | |
AU2018352215A1 (en) | Combination therapy for preventing addiction |